| Excerpt | Reference |
|---|
| "Ulcerative colitis is a disease confined to the colon in an age from 20 to 40 years mainly." | ( Flechsig, U; Richter, P; Seidel, H, 1989) |
| "A child with ulcerative colitis is described in whom many unusual complications of the disease occurred." | ( Moore, TL; Speiser, JC; Zuckner, J, 1985) |
| "Ulcerative colitis is not associated with a higher spontaneous abortion rate than the general population, although it is not clear whether certain subgroups of patients have a higher rate of abortion." | ( Spiro, HM; Vender, RJ, 1982) |
| "Ulcerative colitis is distinguished by abundant prostaglandin E2 (PGE 2) in the stools and by severe diarrhea." | ( Mah, MY; Rood, RP; Sernka, TJ; Tseng, CH, 1982) |
| "Ulcerative colitis is associated with many ocular complications." | ( Burgess, JA; Goy, JA; Lazell, RW; Tesar, PJ, 1981) |
| "Since ulcerative colitis is primarily a mucosal disease, total colectomy with rectal mucosectomy and ileo-endomuscular pull-through (Soave) offers many theoretical advantages." | ( Andrews, HG; Caplan, DB; Zwiren, GT, 1981) |
| "Ulcerative colitis is one of the few diseases in which smoking appears to confer some benefit (1)." | ( Lewis, RA; Watson, JP, 1995) |
| "Ulcerative colitis is frequently associated with extraintestinal inflammatory manifestations." | ( Fretz, C; Hoffman, M; Knoblauch, A; Rickli, H; Walser, A, 1994) |
| "Ulcerative colitis is largely a disease of nonsmokers." | ( Feyerabend, C; Mani, V; Newcombe, RG; Rhodes, J; Russell, MA; Thomas, GA; Williams, GT, 1995) |
| "Ulcerative colitis is a rare disease in young infants." | ( Hoppen, T; Keller, KM; Rister, M; Stolte, M, 1993) |
| "Ulcerative colitis is largely a disease of nonsmokers." | ( Feyerabend, C; Ganesh, S; Mani, V; Morris, JS; Newcombe, RG; Pullan, RD; Rhodes, J; Russell, MA; Thomas, GA; Williams, GT, 1994) |
| "Ulcerative colitis is an illness that occurs unexpectedly in a young patient, with a generally unpredictable prognosis, and there is no medication to cure it." | ( Bigard, MA, 1993) |
| "Ulcerative colitis is a chronic inflammatory disease and the most common form of inflammatory bowel disease, which is a debilitating and unpredictable group of illnesses affecting the gastrointestinal tracts of over 2 million Americans." | ( Claussen, DW, 1993) |
| "The hallmark of ulcerative colitis is a diffuse infiltration of neutrophils from the circulation into the colonic mucosa." | ( Haydek, JM; Keshavarzian, A, 1995) |
| "Ulcerative colitis is a chronic inflammatory disease of the colon that affects the rectum and a variable length of contiguous colon." | ( Das, KM; Griffel, LH, 1996) |
| "Ulcerative colitis is largely a disease of non-smokers." | ( Feyerabend, C; Mani, V; Newcombe, RG; Ragunath, K; Rhodes, J; Russell, MA; Thomas, GA; Williams, GT, 1996) |
| "Ulcerative colitis is a chronic inflammatory disease of the colon where leukotrienes are suggested to play an important role for keeping inflammation active." | ( Ammon, HP; Gupta, I; Lüdtke, R; Malhotra, P; Parihar, A; Safayhi, H; Singh, GB, 1997) |
| "Ulcerative colitis is predominantly a disease of nonsmokers." | ( Batts, KP; Croghan, IT; Dale, LC; Hurt, RD; Lawson, GM; Offord, KP; Petersen, BT; Sandborn, WJ; Schroeder, DR; Tremaine, WJ, 1997) |
| "Ulcerative colitis is largely a disease of nonsmokers, and transdermal nicotine is of therapeutic value in the active disease." | ( Evans, BK; Feyerabend, C; Fuller, GS; Green, JT; Newcombe, RG; Rhodes, J; Russell, MA; Sandborn, WJ; Thomas, GA, 1997) |
| "Ulcerative colitis is associated with abnormalities of mucin synthesis and secretion, features that may also be associated with malignant change." | ( Corfield, AP; Jones, CJ; Mayberry, JF; McMahon, RF; Probert, CS; Stoddart, RW; Warren, BF, 1997) |
| "Ulcerative colitis is predominantly a disease of non-smokers, and transdermal nicotine is therapeutic but often results in side-effects." | ( Batts, KP; Compton, RF; Green, J; Hurt, RD; Lawson, GM; Leighton, JA; Lipsky, JJ; Mays, DC; Offord, KP; Sandborn, WJ; Tremaine, WJ; Zins, BJ, 1997) |
| "Ulcerative colitis is associated with a selective reduction of n-butyrate oxidation by the colonic epithelial cells although the reason for this has been unclear." | ( Babidge, WJ; Millard, SH; Moore, JW; Roediger, WE, 1997) |
| "Refractory ulcerative colitis is best treated surgically." | ( Kam, L, 1998) |
| "Ulcerative colitis is a chronic inflammatory condition characterized by an altered intestinal immunoinflammatory response." | ( Amorosi, A; Calabrò, A; Garcea, MR; Mantellini, P; Paladini, I; Panerai, C; Renzi, D; Salvadori, G; Surrenti, C, 1998) |
| "Ulcerative colitis is predominantly a disease of non-smokers, and transdermal nicotine has therapeutic benefit but causes frequent side-effects." | ( Evans, BK; Feyerabend, C; Green, JT; Rhodes, J; Russell, MA; Sandborn, WJ; Thomas, GA, 1998) |
| "Ulcerative colitis is a nonspecific inflammatory disease of large intestine." | ( Asakura, H, 1998) |
| "Ulcerative colitis is a chronic inflammatory disease state of unknown etiology." | ( Frazee, LA; Slyk, MP, 1997) |
| "Ulcerative colitis is predominantly a disease of nonsmokers and transdermal nicotine has therapeutic value in active disease; however side-effects are troublesome." | ( Evans, BK; Feyerabend, C; Green, JT; Ranshaw, C; Rhodes, J; Russell, MA; Thomas, GA, 1999) |
| "Ulcerative colitis is a condition of nonsmokers in which nicotine is of therapeutic benefit." | ( Green, JT; Marshall, RW; McKirdy, HC; Rhodes, J; Richardson, C; Thomas, GA; Williams, GT, 2000) |
| "Diarrhea in ulcerative colitis is therefore related, at least in part, to a major defect in electrogenic Na+ absorption, which reflects changes in the levels of expression of critical subunits of both the apical Na+ channel and basolateral Na(+)-K(+)-ATPase." | ( Greig, E; Sandle, GI, 2000) |
| "Ulcerative colitis is an inflammatory bowel disease with chronic diarrhea, rectal bleeding and characteristic histological findings." | ( Ala-Mello, S; Kääriäinen, H; Koskimies, O, 2001) |
| "Ulcerative colitis is managed mainly in secondary care by regular outpatient reviews done by specialist clinicians." | ( Roberts, C; Robinson, A; Thompson, DG; Wilkin, D, 2001) |
| "Ulcerative colitis is a chronic inflammatory bowel disorder of unknown etiology." | ( Alexandrowitz, A; Arber, N; Brazowski, E; Dotan, I; Hallak, A; Halpern, Z; Hershkoviz, R; Knaani, Y; Santo, M, 2001) |
| "Ulcerative colitis is characterized by dysfunctional motility." | ( Hussein, SM; Khan, I; Oriowo, M, 2002) |
| "Crohn's disease and ulcerative colitis are characterized by recurrent inflammatory involvement of different intestinal segments involving distinctive urinary patterns." | ( Castelnuovo, C; Lizzano, R; Pisani, E; Trinchieri, A; Zanetti, G, 2002) |
| "Severe ulcerative colitis is conventionally treated with parenteral corticosteroids followed by oral corticosteroids." | ( Awasthi, G; Midha, V; Sood, A; Sood, N, 2002) |
| "Patients with ulcerative colitis are at risk for colon cancer and frequently have microsatellite instability,which, in turn, is usually associated with inactivation of transforming growth factor (TGF) beta signaling." | ( Balish, E; Boivin, GP; Croft, J; Doetschman, T; Engle, SJ; Ormsby, I; Pawlowski, S, 2002) |
| "Crohn's disease and ulcerative colitis are the most frequent inflammatory bowel diseases (IBD) with a prevalence of approximately one out of 500." | ( Göke, B; Ochsenkühn, T; Sackmann, M, 2003) |
| "Ulcerative colitis is a chronic inflammatory disease of the colon of unknown cause." | ( Kane, SV; Tuvlin, JA, 2003) |
| "Ulcerative colitis is a chronic inflammatory bowel disease." | ( Kullak-Ublick, GA; Rammert, Ch, 2003) |
| "In humans, ulcerative colitis is normally treated with aminosalicylates (ASAs) and corticosteroids (CSs) to reduce inflammation." | ( Brubaker, PL; L'Heureux, MC, 2003) |
| "Steroid refractory ulcerative colitis is most commonly treated with intravenous ciclosporin to avoid colectomy." | ( Hinterleitner, TA; Högenauer, C; Petritsch, W; Wenzl, HH, 2003) |
| "In the early stages ulcerative colitis is reversible and a normal bowel can be regained." | ( JONES, FA, 1955) |
| "Patients with ulcerative colitis are at increased risk of colorectal cancer." | ( Forbes, A; Kamm, M; Price, A; Rumbles, S; Rutter, M; Saunders, B; Schofield, G; Talbot, I; Wilkinson, K; Williams, C, 2004) |
| "Severe ulcerative colitis is potentially life threatening even though a policy of intensive medical management and early colectomy in recent years reduced mortality to almost zero." | ( Daperno, M; Ercole, E; Pera, A; Rigazio, C; Rocca, R; Scaglione, N; Sostegni, R, 2004) |
| "Ulcerative colitis is characterized by chronic inflammation of the colon." | ( Fölsch, UR; Kühbacher, T; Schreiber, S, 2004) |
| "Left-sided ulcerative colitis is not a distinct entity, but a less extensive form of pancolitis." | ( Haghighi, DB; Lashner, BA, 2004) |
| "Ulcerative colitis is an inflammatory bowel disease often associated with extra-intestinal manifestations, such as dermatological disorders." | ( Amantea, A; Consolazio, A; Crispino, P; Di Palma, V; Iacopini, F; Paoluzi, OA; Paoluzi, P; Pica, R; Rivera, M, 2004) |
| "Ulcerative colitis is largely a disease of nonsmokers." | ( Macdonald, JK; McDonald, JW; McGrath, J, 2004) |
| "Ulcerative colitis is associated with altered contractile activity and transit time of colon." | ( Al Moutaery, A, 2005) |
| "Ulcerative colitis is a common inflammatory bowel disease (IBD) of unknown etiology." | ( Arafah, M; El-Medany, A; Mahgoub, A; Moursi, M; Mustafa, A, 2005) |
| "Patients with ulcerative colitis are at greater risk of developing colorectal cancer than the general population." | ( Biasco, G; Di Marco, MC, 2005) |
| "Ulcerative colitis is a chronic relapsing or chronic active disease which starts at the rectum and presents with a continuous inflammation." | ( Siegmund, B; Zeitz, M, 2005) |
| "Ulcerative colitis is a chronic inflammatory and debilitating disease requiring lifelong treatment." | ( Kane, SV, 2006) |
| "Ulcerative colitis is a frequent chronic inflammatory boxel disease." | ( Chemli, S; Hammami, W; Jebali, A; Rym, D, 2006) |
| "Ulcerative colitis is associated with elevated tHcy concentration, particularly in the active stage, and in more recurrent types of the disease; this elevation does not seem to be prevented by a normal folate status and might have an enhancing effect on the procoagulation blood profile." | ( Bald, E; Czupryniak, L; Drzewoski, J; Gasiorowska, A; Małecka-Panas, E, 2006) |
| "Relapse of ulcerative colitis is difficult to predict by routine colonoscopy." | ( Ando, T; Goto, H; Ishiguro, K; Kusugami, K; Maeda, O; Nishio, Y; Niwa, Y; Ohmiya, N; Watanabe, O, 2006) |
| "Ulcerative colitis is a chronically recurrent inflammatory bowel disease of unknown origin." | ( Arafa, M; El-Eter, E; El-Medany, A; Hagar, HH, 2007) |
| "Severe ulcerative colitis is therefore considered a medical emergency, the management of which requires close collaboration between gastroenterologists and surgeons." | ( Caprilli, R; Latella, G; Viscido, A, 2007) |
| "Ulcerative colitis is characterised by impairment of the epithelial barrier and tight junction alterations resulting in increased intestinal permeability." | ( Heavey, PM; McGilligan, VE; Ridley, DL; Rowland, IR; Wallace, JM, 2007) |
| "Ulcerative colitis is a chronic inflammatory disease of the gastrointestinal tract." | ( Bardini, KC; Benetton, CA; Cardoso, VH; Dal-Pizzol, F; Damiani, CR; Di Giunta, G; Pinho, RA; Stoffel, C; Streck, EL, 2007) |
| "Crohn's disease and ulcerative colitis are two idiopathic inflammatory bowel disorders." | ( Baumgart, DC; Sandborn, WJ, 2007) |
| "Ulcerative colitis is characterized by relapsing mucosal inflammation where the lesions include tissue-damaging granulocytes." | ( Bjartell, A; Carlson, M; Egesten, A; Eliasson, M; Erjefält, JS; Olin, AI; Sangfelt, P, 2007) |
| "Ulcerative colitis is a chronic inflammatory disease of the colon and rectum." | ( Abbasoğlu, SD; Barbaros, U; Erbil, Y; Giriş, M; Necefli, A; Olgaç, V; Toker, GA; Yanik, BT, 2007) |
| "Ulcerative colitis is a chronic inflammatory bowel disease." | ( Chande, N; MacDonald, JK; McDonald, JW, 2007) |
| "Ulcerative colitis is a chronic disease with recurrent symptoms and significant morbidity." | ( Gotsch, PB; Krafczyk, MA; Langan, RC; Skillinge, DD, 2007) |
| "Ulcerative colitis is an inflammatory bowel disease of uncertain etiology with recurrent symptoms and considerable morbidity." | ( Dalal, L, 2007) |
| "Severe ulcerative colitis is a potentially life-threatening condition." | ( Aratari, A; Caprilli, R; Capurso, L; Clemente, V; Koch, M; Luchetti, R; Moretti, A; Papi, C, 2008) |
| "The aetiology of ulcerative colitis is uncertain but may relate to environmental factors in genetically predisposed individuals." | ( Coffey, JC; Docherty, NG; O'Connell, PR; Rowan, FE, 2009) |
| "Patients with ulcerative colitis are at increased risk for developing colorectal cancer." | ( Abreu, MT; Breglio, K; Chen, A; Cohen, J; Conduah, D; Fukata, M; Goo, T; Hernandez, Y; Hsu, D; Xu, R, 2009) |
| "Ulcerative colitis is also in complete remission stage." | ( Baba, HA; Gerken, G; Kahraman, A; Maldonado-Lopez, E; Miller, M; Treichel, U, 2009) |
| "Patients with ulcerative colitis are at risk for colorectal cancer (CRC)." | ( Bryant, SC; Garrity-Park, MM; Loftus, EV; Sandborn, WJ; Smyrk, TC, 2009) |
| "Crohn's disease and ulcerative colitis are chronic inflammatory disease of the intestine,which frequently require surgery for complications or failure of medical therapy." | ( Bosques-Padilla, FJ; Galindo-Marines, SL; Yamamoto-Farusho, JK, 2008) |
| "Ulcerative colitis is a chronic relapsing and remitting inflammatory disorder that can generally be managed successfully with maintenance oral medications." | ( Cheifetz, AS; Doherty, GA, 2009) |
| "Ulcerative colitis is an intractable inflammatory colonic disease, and its etiology remains unclear." | ( Fujiwara, K; Kadowaki, M; Kageyama-Yahara, N; Kuramoto, H; Shimada, Y; Watanabe, T; Yamamoto, T; Yoshida, M, 2010) |
| "Ulcerative colitis is a nonspecific inflammatory disorder characterized by oxidative and nitrosative stress, leucocyte infiltration and upregulation of inflammatory mediators." | ( Cárdeno, A; de la Lastra, CA; Sánchez-Fidalgo, S; Talero, E; Villegas, I, 2010) |
| "Ulcerative colitis is an autoimmune-inflammatory disease characterized by abnormally increased expression of Toll-like receptor-4 (TLR4) in colonic epithelial cells, increased production of pro-inflammatory cytokines (e." | ( Benavides, U; Dagia, NM; Deosarkar, SP; Goetz, DJ; Gonzalez-Murguiondo, M; Harii, N; Kohn, LD; Kurjiaka, DT; Lewis, CJ; Sakhalkar, HS, 2010) |
| "Ulcerative colitis is a chronically recurrent inflammatory bowel disease of unknown origin." | ( Hassan, GS; Soliman, GA, 2010) |
| "Ulcerative colitis is a chronic condition that requires long-term treatment." | ( Bernick, SJ; Kane, S, 2010) |
| "Crohn's disease and ulcerative colitis are clinically, immunologically, and morphologically distinct forms of inflammatory bowel disease (IBD)." | ( Sarna, SK; Shi, XZ; Winston, JH, 2011) |
| "Acute severe ulcerative colitis is a potentially lethal condition that requires a pro-active approach with either effective medical treatment or timely colectomy." | ( Rutgeerts, P; Van Assche, G; Vermeire, S, 2011) |
| "Ulcerative colitis is presenting with increasing severity and extent in recent times." | ( Ray, G, 2011) |
| "Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment." | ( Avellini, C; Fabro, M; Fiorino, G; Sorrentino, D; Szabo, H; Tabuso, M; Terrosu, G, 2011) |
| "Ulcerative colitis is a nonspecific inflammatory disorder characterized by oxidative and nitrosative stress, leucocyte infiltration and up-regulation of pro-inflammatory cytokines." | ( He, J; Liang, J; Sun, W; Zhang, Y; Zhao, W; Zhu, S, 2011) |
| "Ulcerative colitis is a chronic inflammatory condition associated with a high colon cancer risk." | ( Chumanevich, A; Chumanevich, AA; Davis, T; Hofseth, AB; Hofseth, LJ; Le, PM; Nagarkatti, M; Nagarkatti, PS; Poudyal, D; Wargovich, MJ; Windust, A, 2012) |
| "Crohn's disease and ulcerative colitis are inflammatory bowel diseases characterised by a chronic relapsing course." | ( Aratari, A; Chiesara, F; Doddato, MT; Fascì Spurio, F; Margagnoni, G; Papi, C, 2012) |
| "Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective." | ( Ghosh, S; Niezychowski, W; Panes, J; Rousell, S; Sandborn, WJ; Su, C; Vranic, I, 2012) |
| "Ulcerative colitis is an idiopathic, chronic inflammatory disorder of the colonic mucosa, which starts in the rectum and generally extends proximally in a continuous manner through part of, or the entire, colon; however, some patients with proctitis or left-sided colitis might have a caecal patch of inflammation." | ( Baumgart, DC; Eckmann, L; Ordás, I; Sandborn, WJ; Talamini, M, 2012) |
| "Ulcerative colitis is less prevalent in smokers." | ( Leong, RW; Lunney, PC, 2012) |
| "Ulcerative colitis is far more common than Crohn's disease in our setting." | ( Adkar, S; Jain, AK; Jain, M; Sircar, S; Waghmare, C, 2012) |
| "Crohn's disease and ulcerative colitis are highly related genetically." | ( Abreu, MT; Strobel, S, 2013) |
| "Ulcerative colitis is a chronic recurrent disease characterized by acute inflammation of the colonic mucosa." | ( Fukushima, T; Hamasaki, A; Harada, N; Hayashi, T; Inagaki, N; Joo, E; Matsunaga, T; Muraoka, A; Nasteska, D; Shide, K; Suzuki, K; Tsuda, K; Tsuji, H; Yamane, S, 2013) |
| "Ulcerative colitis is an inflammatory bowel disease, clinical presentation is not specific and may mimic Crohn's disease, radiation colitis, ischemic colitis, a variety of infectious processes, and colitis related to medications." | ( Azak, A; Duranay, M; Huddam, B; Kiliç, F; Koçak, E; Koçak, G, 2012) |
| "The treatment of ulcerative colitis is based on systemic corticosteroids, immunomodulators such as cyclosporine and azathioprine and TNF-α antagonists." | ( Hartmann, F; Stein, J; Tannich, E, 2013) |
| "Ulcerative colitis is a chronic inflammatory disease and involves multiple etiological factors." | ( Chen, X; Ding, B; Hou, Y; Liu, Y; Long, M; Wang, L; Wang, Q; Wu, G; Yi, D, 2013) |
| "Ulcerative colitis is a chronic inflammatory disorder characterized by oxidative stress, leucocyte infiltration and upregulation of pro-inflammatory cytokines." | ( Guruvayoorappan, C; Sakthivel, KM, 2013) |
| "Ulcerative colitis is a chronic inflammatory disease of the colon of unknown cause that is characterized by alternating intervals of active and inactive disease in 80-90% of patients." | ( Blonski, W; Buchner, AM; Lichtenstein, GR, 2014) |
| "Ulcerative colitis is an inflammatory disease that involves only the colon and rectum, being characterized by leukocyte infiltrate and superficial ulcers in the intestinal mucosa." | ( Fillmann, HS; Hartmann, RM; Marroni, NP; Martins, MI; Meurer, L, 2014) |
| "Ulcerative colitis is an inflammatory bowel disease characterized by acute inflammation, ulceration, and bleeding of the colonic mucosa." | ( Tun, X; Yamada, K; Yasukawa, K, 2014) |
| "Ulcerative colitis is associated with an alteration in gonadal hormones and affects testicular weight in rodents." | ( Jena, GB; Parmar, AR; Trivedi, PP, 2014) |
| "Ulcerative colitis is a chronic idiopathic inflammatory bowel disease characterized by continuous mucosal inflammation that starts in the rectum and extends proximally." | ( Cheifetz, AS; Feuerstein, JD, 2014) |
| "Crohn's disease and ulcerative colitis are chronic inflammatory conditions affecting the gut and can present at any age with increased numbers of diagnoses seen in many countries in recent years." | ( Day, AS; Ledder, O; Lemberg, DA, 2015) |
| "Ulcerative colitis is a chronic inflammatory bowel disease." | ( Ahmed, MA; El Morsy, EM; Kamel, R, 2015) |
| "Ulcerative colitis is a chronic inflammatory condition in which the inflammatory response confined to the colon." | ( Bijjem, KR; Goyal, N; Kumar, P; Rana, A, 2015) |
| "Ulcerative colitis is a chronic disease having a regressive nature." | ( El-Kawy, OA; Farah, K; Ibrahim, IT, 2015) |
| "Ulcerative colitis is an inflammatory disorder characterized by neutrophils infiltration, oxidative stress, upregulation of pro-inflammatory mediators and cytokines." | ( He, Z; Li, W; Mu, Q; Niu, X; Wang, X; Wang, Y; Yao, H; Zhang, H, 2015) |
| "Ulcerative colitis is associated with a considerable reduction in the quality of life of patients." | ( Kumar, JM; Kuncha, M; Medicherla, K; Sahu, BD; Sistla, R; Sudhakar, G, 2015) |
| "Ulcerative colitis is a major inflammatory bowel disease (IBD), characterized by inflammation within the gastrointestinal tract through chronic or relapsing immune system activation." | ( Chen, Y; Lin, Q; Liu, B; Luo, F; Shi, L; Yang, T; Zeng, L, 2015) |
| "The patient of ulcerative colitis is increasing every year and it is anticipated that the patient with mesalazine-induced pneumonia may also increase." | ( Abe, T; Akiyama, N; Matsui, T; Nozue, T; Suda, T; Yokomura, K, 2015) |
| "Ulcerative colitis is a chronic nonspecific inflammatory disease of unknown cause." | ( He, J; Huo, C; Li, J; Lv, L; Sun, W; Suo, Y; Wang, J; Wang, Z; Yang, Y; Zhang, Y; Zheng, Z, 2016) |
| "Ulcerative colitis is an immunologic disorder of the intestine which involves the mucosa and sometimes the submucosa." | ( Biedermann, L; D'cunja, J; Roose, L, 2016) |
| "Ulcerative colitis is a lifelong, immunologically mediated disease." | ( Arai, M; Haga, Y; Kanda, T; Katsuno, T; Nakamoto, S; Nakamura, M; Ohta, Y; Sasaki, R; Wu, S; Yasui, S; Yokosuka, O, 2016) |
| "Treatment of active ulcerative colitis is associated with incomplete efficacy, adverse events, and loss of response." | ( Adar, T; Chowers, Y; Dotan, I; Fich, A; Goldin, E; Israeli, E; Levy-Nissenbaum, E; Shteingart, S; Soreq, H, 2016) |
| "Ulcerative colitis is a common chronic inflammatory disease of the colon and rectum, resulting from a dysregulated immune response towards intraluminal antigens in a genetically predisposed host." | ( D'Haens, G; Hindryckx, P; Jairath, V, 2016) |
| "Ulcerative colitis is a chronic inflammatory disease affecting the colon and is characterized by epithelial damage and barrier dysfunction." | ( Balendran, CA; Böttcher, G; Eckersley, S; Henderson, N; Hughes, G; Nyström, AC; Price, SA; Randall, K; Reens, J; South, MC, 2016) |
| "The main symptom of ulcerative colitis is diarrhoea, which is often accompanied by painful tenesmus and faecal blood and mucus." | ( Guzek, D; Głąbska, D; Lech, G; Włodarek, D; Zakrzewska, P, 2016) |
| "Ulcerative colitis is a chronic inflammatory disease affecting the colon, and its incidence is rising worldwide." | ( Allen, PB; Colombel, JF; Mehandru, S; Peyrin-Biroulet, L; Ungaro, R, 2017) |
| "Ulcerative colitis is a relapsing inflammatory disorder of the colon." | ( Ghasemi-Pirbaluti, M; Hosseini, MJ; Motaghi, E; Najafi, A, 2017) |
| "Ulcerative colitis is majorly associated with oxidative stress and inflammation in colon tissue leading to damage." | ( Berlin Grace, VM; Guruvayoorappan, C; Sakthivel, KM; Suluvoy, JK, 2017) |
| "Crohn's disease and ulcerative colitis are the two major types of inflammatory bowel disease, and affect mainly the gastrointestinal tract but also have extraintestinal sequelae, such as arterial and venous thromboembolism." | ( Jang, S; Kang, SB; Kim, SH; Park, JK; Park, Y; Sung, Y; Yun, J, 2017) |
| "Ulcerative colitis is one of the most common types of inflammatory bowel disease and is multifactorial and relapsing." | ( Gao, YF; Ma, N; Sun, LL; Zhang, F; Zhang, JG, 2017) |
| "Ulcerative colitis is a well-known inflammatory bowel disease." | ( Abe, H; Fujita, Y; Ishida, N; Ishioka, M; Nakajima, Y; Ohnishi, S; Sato, A; Shichiri, M; Suzuki, S; Umeno, A; Yasunaga, M; Yoshida, Y, 2018) |
| "Ulcerative colitis is a chronic and recurrent inflammatory disease involving the intestine." | ( Dong, W; Liu, Z; Tian, S; Zhou, K, 2018) |
| "Ulcerative colitis is a type of chronic inflammation present in the intestines for which the aetiology is not yet clear." | ( Dou, J; Fan, H; Fang, K; Gu, Y; Mao, K; Wang, H; Wang, Y; Zhou, C, 2018) |
| "Ulcerative colitis is characterized by colonic mucosal bleeding and ulceration, often with repeated active and remission stages." | ( Tun, X; Yamada, KI; Yasukawa, K, 2018) |
| "Acute severe ulcerative colitis is a life-threatening medical emergency, which can be associated with significant morbidity and is preventable through prompt and effective management." | ( Ahuja, V; Jain, S; Limdi, JK, 2019) |
| "Ulcerative colitis is a chronic inflammatory bowel disease with high incidence and prevalence worldwide." | ( Ariakia, F; Avan, A; Bahreyni, A; Behnam-Rassouli, R; Hashemzehi, M; Hassanian, SM; Khazaei, M; Moradi Marjaneh, R; Pashirzad, M; Rahmani, F; Rezaei, N; Ryzhikov, M; Shafiee, M, 2020) |
| "BACKGROUND Ulcerative colitis is a chronic, idiopathic inflammatory disease that destroys the colon structure." | ( Du, B; Liu, B; Lu, Y; Shi, Y; Sun, M; Zhou, Y, 2019) |
| "Background Ulcerative colitis is a chronic mucosal inflammation of the large intestine mainly affecting the colon and rectum." | ( Bali, A; Jaggi, AS; Kaur, G; Walia, D, 2019) |
| "Ulcerative colitis is a chronic inflammatory disorder characterized by oxidative stress and upregulation of proinflammatory mediators in colonic tissue." | ( Amirshahrokhi, K, 2019) |
| "Ulcerative colitis is a chronic auto-inflammatory disorder confined to the colorectal region." | ( Abu-Risha, SE; Amer, MS; El-Mahdy, NA; Saleh, DA, 2020) |
| "Ulcerative colitis is an inflammatory bowel disease that affects the mucous membrane of the colon." | ( Barros, SÉL; Bráz, DC; da Silva, AS; de Moura, MSB; de Pinho, FA; Lima, MM; Marreiro, DDN; Nogueira, NDN; Parente, JML; Silva, TMC; Soares, NRM; Vieira, EC, 2020) |
| "Acute severe ulcerative colitis is a high stakes event with significant numbers still requiring emergent colectomy, representing a need to establish alternative medical management options." | ( Kotwani, P; Lewin, S; Terdiman, J, 2020) |
| "Ulcerative Colitis is a universal autoimmune disease with high incidence rates worldwide." | ( Arafa, EA; Mohamed, WR; Omar, HA; Zaher, DM, 2020) |
| "Ulcerative colitis is an inflammatory condition affecting the colon, with an annual incidence of approximately 10 to 20 per 100,000 people." | ( Akobeng, AK; Baines, PA; Gordon, M; Iheozor-Ejiofor, Z; Kaur, L; Sinopoulou, V, 2020) |
| "Ulcerative colitis is an inflammatory condition affecting the colon, with an annual incidence of approximately 10 to 20 per 100,000 people." | ( Akobeng, AK; Baines, PA; Gordon, M; Iheozor-Ejiofor, Z; Kaur, L; Sinopoulou, V, 2020) |
| "Ulcerative colitis is a chronic inflammatory disease involving the colon and rectum." | ( Choi, S; Coburn, ES; Holubar, SD; Levy, LC, 2020) |
| "Ulcerative colitis is a chronic mucosal inflammatory condition that adversely affects colon and rectum." | ( Ahmad, A; Khan, R; Kumar, A; Mishra, RK; Raza, SS; Vyawahare, A, 2020) |
| "Ulcerative colitis is an incurable condition whereby patients are at an increased risk of developing colorectal cancer (CRC)." | ( Chartier, LC; Howarth, GS; Mashtoub, S; Trinder, D, 2021) |
| "Ulcerative colitis is one of the IBD which cause a chronic intestinal inflammation and dysfunctional of the mucosal barrier." | ( Cai, C; Chen, Q; Jin, S; Li, N; Yang, B; Zhao, D, 2020) |
| "Ulcerative colitis is a common intestinal inflammatory disease." | ( Luo, M; Luo, Y, 2021) |
| "Crohn's and ulcerative colitis are common inflammatory conditions associated with Inflammatory bowel disease." | ( Bhadada, SK; Bhatia, R; Bishnoi, M; Kaur, J; Khare, P; Kondepudi, KK; Rajarammohan, S; Sharma, S; Sharma, SS; Singh, S, 2020) |
| "Ulcerative colitis is a chronic inflammatory bowel disease with an estimated 150 000 patients in Germany alone." | ( Dignass, A; Kannengiesser, K; Koletzko, S; Kucharzik, T, 2020) |
| "Ulcerative colitis is a chronic gastrointestinal disease characterized by intestinal inflammation and serious mucosal damage." | ( Li, D; Qian, B; Ren, Y; Song, JL; Wang, C; Zeng, Z, 2020) |
| "Ulcerative colitis is common types of severe, progressive, idiopathic inflammatory bowel disease that involves the mucosal lining of the large intestine." | ( Ingawale, DK; Mandlik, SK; Patel, SS, 2021) |
| "Ulcerative colitis is a gut inflammatory disorder due to altered immune response to gut microbiome, with interplay of environmental and genetic factors." | ( Abdallah, HM; El-Halawany, AM; Murad, HAS; Rafeeq, M, 2021) |
| "Ulcerative colitis is an autoimmune inflammatory disorder with a negative impact on the life quality of patients." | ( Abdelaleem, EA; Elhennawy, MG; Mohamed, WR; Zaki, AA, 2021) |
| "Acute severe ulcerative colitis is a medical emergency that warrants in-patient management." | ( Rosiou, K; Selinger, CP, 2021) |
| "Patients with ulcerative colitis are typically suspected of an inflammatory flare based on suggestive symptoms of inflammation." | ( Chen, J; Chen, JDZ; Chen, Y; Gharibani, P; Guo, Y; Selaru, FM, 2021) |
| "Ulcerative colitis is a chronic inflammatory condition of the gastrointestinal tract that can affect people of worldwide." | ( Alesci, A; Cutroneo, G; Favaloro, A; Lauriano, ER; Melita, G; Pallio, S; Pergolizzi, S; Rizzo, G, 2021) |
| "Ulcerative colitis is a form of inflammatory bowel disease that is characterized by acute and chronic inflammation." | ( Fokam Tagne, MA; Kamgang, R; Kom, B; Mazo, AG; Ngakou Mukam, J; Noubissi, PA; Sokeng Dongmo, S; Tchoffo, A, 2021) |
| "Ulcerative colitis is a subtype of inflammatory bowel disease, characterized by relapsing inflammation in the gastrointestinal tract with limited treatment options." | ( Chen, SG; Kwok, HF; Lau, CB; Lee, JK; Li, XX; Shaw, PC; Simmonds, MSJ; Yue, GG; Zheng, T, 2021) |
| "Ulcerative colitis is a common non-specific chronic disease." | ( Li, S; Xiao, D; Yin, Y; Zou, Y, 2021) |
| "Ulcerative colitis is an inflammatory bowel disease that forms ulcerations in the mucous membrane of the colon and rectum, in which gut microbiota plays a pivotal role in its pathogenesis." | ( Aljofan, M; Babenko, D; Chulenbayeva, L; Gulyayev, A; Kozhakhmetov, S; Kozhakhmetova, S; Kushugulova, A; Muhanbetganov, N; Nurgaziyev, M; Nurgozhina, A; Sergazy, S; Tuyakova, A, 2022) |
| "Ulcerative colitis is a recurrent inflammatory illness of the colon with an elevated risk of developing colon cancer." | ( Bettadaiah, BK; Mathew, NS; Muthukumar, SP; Negi, PS, 2022) |
| "Ulcerative colitis is the most prevalent forms of inflammatory bowel diseases and a refractory autoimmune disease and affects millions of people worldwide." | ( Ouyang, J; Sun, L; Wu, S; Zeng, F, 2022) |
| "Ulcerative colitis is a chronic inflammatory bowel disease." | ( Juillerat, P; Laharie, D; Nachury, M; Pellet, G; Roblin, X; Veyrard, P, 2023) |
| "Ulcerative colitis is a complex inflammatory bowel disorder disease that can induce rectal and colonic dysfunction." | ( Kim, HW; Kim, JS; Lee, BS; Lee, JW; Lee, SK; Lee, YI; Park, HW; Whang, J; Yoon, HS; Yu, AR, 2022) |
| "Ulcerative colitis is a chronic inflammatory bowel disease involving a dysregulated immune response in the intestinal mucosa." | ( Paik, J, 2022) |
| "Ulcerative colitis is an idiopathic disease that is widely incident worldwide." | ( Abdelhamid, AM; Amin, NA; Cavalu, S; El-Ahwany, E; El-Azez, RA; El-Rafi, AA; El-Sandarosy, R; Elagamy, HI; Essam, M; Essam, N; Gaafar, AGA; Girgis, S; Hasaballah, A; Kamal, I; Mahmoud, F; Mansour, M; Mohamed, D; Mohammed, OA; Nasr, M; Rizk, H; Saber, S; Youssef, ME, 2022) |
| "Crohn's disease and ulcerative colitis are the two main forms of IBD." | ( Abdalkareem Jasim, S; Hosseini-Fard, SR; Jawad, MA; Kamal Abdelbasset, W; Karampoor, S; Mahmudiono, T; Mirzaei, R; Mohammad, HJ; Rudiansyah, M; S Azizov, B; Samusenkov, V; Yasin, G, 2022) |
| "Ulcerative colitis is a unique inflammatory bowel disease with ulcerative lesions of the colonic mucosa." | ( He, Y; Ma, X; Shen, J; Wang, Y; Zhang, Y; Zhong, T, 2022) |
| "Ulcerative colitis is an inflammatory bowel disease characterized by symptoms such as abdominal pain, diarrhea, bleeding, and weight loss." | ( Kim, SK; Park, SY; Yeom, JE, 2022) |
| "Ulcerative colitis is an inflammatory bowel disease characterized by symptoms such as abdominal pain, diarrhea, bleeding, and weight loss." | ( Kim, SK; Park, SY; Yeom, JE, 2022) |
| "Ulcerative colitis is an inflammatory bowel disease characterized by symptoms such as abdominal pain, diarrhea, bleeding, and weight loss." | ( Kim, SK; Park, SY; Yeom, JE, 2022) |
| "Ulcerative colitis is a multifactorial disease of the gastrointestinal tract which is caused due to chronic inflammation in the colon; it usually starts from the lower end of the colon and may spread to other portions of the large intestine, if left unmanaged." | ( Ahmad, A; Khan, R; Kumar, A; Mishra, RK; Nadeem, A; Raza, SS; Sakla, R; Siddiqui, N; Vyawahare, A, 2023) |
| "Ulcerative colitis is a multifactorial disease of the gastrointestinal tract which is caused due to chronic inflammation in the colon; it usually starts from the lower end of the colon and may spread to other portions of the large intestine, if left unmanaged." | ( Ahmad, A; Khan, R; Kumar, A; Mishra, RK; Nadeem, A; Raza, SS; Sakla, R; Siddiqui, N; Vyawahare, A, 2023) |
| "Ulcerative colitis is a chronic inflammatory bowel disorder that is hard to cure once diagnosed." | ( Chen, H; Jiang, R; Lian, Q; Sha, W; Tu, S; Wu, H; Yang, Q; Zeng, R; Zhuo, Z, 2022) |
| "Ulcerative colitis is a type of inflammatory bowel disease responsible for the inflammation of the innermost lining of the colon and rectum." | ( Cheng, H; Wang, Q; Yin, Z, 2023) |
| "Ulcerative colitis is a condition of chronic inflammation affecting the large intestine." | ( Basnet, BK; Bhandari, A, 2022) |
| "Ulcerative colitis is a chronic inflammatory bowel disease caused by the body's inability to control its immune system." | ( Peyrin-Biroulet, L; Wils, P, 2023) |
| "Ulcerative colitis is an inflammatory condition with ulcerations throughout the colon." | ( Baranauskaite, J; Özdemir, S; Sümer, E; Üner, B; Yaba, A; Yıldırım, E, 2023) |
| "Ulcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the intestinal inflammation extent and duration." | ( Jeon, SM; Kim, HH; Kim, K; Kim, KY; Kim, YJ; Shin, CS; Song, YH; Yoon, JW, 2023) |
| "Pediatric ulcerative colitis is likely to be more severe than adult ulcerative colitis." | ( Fukura, S; Ichihara, Y; Kondo, S; Mori, K; Ono, A; Shichijo, K; Suzuki, Y; Takei, M; Takeuchi, S; Tayama, T, 2023) |
| "Ulcerative colitis is characterized by colonic inflammation." | ( Howarth, GS; Mashtoub, S, 2023) |
| "Ulcerative colitis is characterized as a chronic immune-mediated inflammatory condition, affecting the intestinal gastroenteric tissue." | ( Bhatt, LK; Parihar, N, 2023) |
| "Ulcerative colitis is an inflammation-related disease with a high recurrence risk." | ( Jiao, X; Liu, C; Wang, R; Wang, Z; Zhang, C; Zhang, J, 2023) |
| "Ulcerative colitis is a chronic inflammation of the colon." | ( Amini-Khoei, H; AnjomShoa, M; Ghasemi-Dehnoo, M; Lorigooini, Z; Rafieian-Kopaei, M, 2023) |
| "Ulcerative colitis is a lifelong inflammatory disease affecting the rectum and colon to a variable extent." | ( Honap, S; Le Berre, C; Peyrin-Biroulet, L, 2023) |
| "Ulcerative colitis is a relapsing and remitting disease that may be associated with flares." | ( Dutta, U; Jearth, V; Mahajan, G; Patil, AN; Rana, VS; Saroch, A; Sekar, A; Sharma, V; Singh, AK; Singh, H, 2023) |
| "Ulcerative colitis is a chronic inflammatory disease with high mortality and morbidity worldwide." | ( Abu-Raghif, A; Jaafar, FR, 2023) |
| Excerpt | Reference |
|---|
| "In a high percentage of patients with ulcerative colitis good results are obtained with conservative therapy, using salazopyridine alone or in combination with cortisone." | ( Belohlavek, D; Koch, H; Morl, M, 1976) |
| "Sixty-four outpatients with ulcerative colitis receiving maintenance treatment with sulphasalazine were studied to relate disease activity to serum concentrations of sulphapyridine." | ( Cowan, GO; Das, KM; Eastwood, MA, 1977) |
| "In a 25-year old woman with ulcerative colitis a lupus erythematosus syndrome occurred during treatment with salazosulfapyridine." | ( Jaup, BH, 1978) |
| "A case of ulcerative colitis with defective neutrophil chemotaxis, improved after short sulfasalazine therapy, is reported." | ( Dallegri, F; Patrone, F; Sacchetti, C, 1978) |
| "Patients with ulcerative colitis in remission were randomly allocated to treatment with sulphasalazine (2 g/day) or oral sodium cromoglycate (160 mg/day or 2 g/day), and the relapse rates in these treatment groups were compared during continued treatment for one year." | ( Dronfield, MW; Langman, MJ, 1978) |
| "There were no deaths directly due to ulcerative colitis or to surgical treatment in these patients during the period of the study, the mean period of follow-up being 25 months; but 4 elderly patients died from unrelated causes." | ( Kettlewell, MG; Lee, EG; Truelove, SC; Willoughby, CP, 1978) |
| "It is important to distinguish between ulcerative colitis and Crohn's colitis because response to treatment and prognosis are different." | ( Ament, ME, 1975) |
| "The remission period of patients with ulcerative colitis was extended by long term treatment with 2-3 g sulphasalazine daily." | ( Malchow, H, 1979) |
| "The link between ulcerative colitis, the chronic hepatopathy and the development of Hodgkin's disease that could have arisen as a consequence of the prolonged immunosuppressive treatment are discussed." | ( Findor, JA; Orbuch, SJ, 1979) |
| "In patients with ulcerative colitis and enhanced alkaline phosphatases, elevated liver copper content should be suspected and chelation therapy should be considered." | ( Elgjo, K; Johansen, O; Ritland, S; Steinnes, E, 1979) |
| "In 51 untreated cases of ulcerative colitis and Crohn's disease some cellular (neutrophil alkaline phosphatase activity, neutrophil NBT reducing capacity, and neutrophil and plasma lysozyme activities) and humoral (serum orosomucoid and serum haptoglobin) indices of disease activity were quantitated." | ( Klitgaard, NA; Koldkjaer, O; Schmidt, KG, 1978) |
| "100 patients with ulcerative colitis in remission were recruited at one centre and assigned randomly to treatment with olsalazine (Dipentum; 1." | ( Bergin, CF; Courtney, MG; Keeling, PW; Nunes, DP; O'Driscoll, M; Trimble, V; Weir, DG, 1992) |
| "The standard therapy of ulcerative colitis and Crohn's disease is based on the treatment with corticosteroids, sulfasalazine and 5-aminosalicylic acid (mesalazine)." | ( Fischbach, W, 1992) |
| "Two men with longstanding ulcerative colitis who were treated with sulphasalazine for several years and who developed chronic renal failure are reported." | ( Allan, RN; Dwarakanath, AD; Michael, J, 1992) |
| "(2) Mucosal bleeding, characteristic of ulcerative colitis, as well as supplemental oral iron therapy for chronic anemia, further conspire to maintain or elevate mucosal iron concentration in colitis." | ( Babbs, CF, 1992) |
| "We report a case of ulcerative colitis (UC) in a 15 year old female undergoing treatment for anemia with oral ferrous sulfate." | ( Hamamoto, T; Kasajima, Y; Kawai, M; Sumimoto, S, 1992) |
| "A new paradigm for the treatment of ulcerative colitis has recently been presented: Treatment of the mucosa with lidocaine (2%) enemas for prolonged periods." | ( Ahlman, H; Björck, S; Dahlström, A; Johansson, L, 1992) |
| "Azathioprine maintenance treatment in ulcerative colitis is beneficial for at least two years if patients have achieved remission while taking the drug." | ( Axon, AT; Foster, PN; Hawkey, CJ; Hawthorne, AB; Lennard-Jones, JE; Logan, RF; Scott, BB; Swarbrick, ET, 1992) |
| "The cases of two patients with ulcerative colitis are described who developed pulmonary infiltrates during the early months of treatment with sulphasalazine." | ( Ekfors, T; Leino, R; Liippo, K, 1991) |
| "A prophylactic therapy is indicated in ulcerative colitis, an interruption is rarely to be proved." | ( Hänert, E; Schneider, W, 1991) |
| "During successful treatment of active ulcerative colitis normalization of serum retinol levels without substitution of vitamin A was observed." | ( Bartnik, W; Butruk, E; Janczewska, I; Kazik, E; Ostrowski, J; Tomecki, R, 1991) |
| "Basis treatment of severe ulcerative colitis and Crohn's disease comprises the systemic administration of corticosteroids." | ( Kreisel, W; Rasenack, J, 1991) |
| "Three patients suffering from ulcerative colitis, who had previously undergone a colectomy and temporary Brooke ileostomy and who were under treatment with methylprednisolone and 5-aminosalicylic acid per the rectum, were readmitted to the hospital, presenting with profuse rectal hemorrhage with six to nine blood losses per day." | ( Ceccarino, R; Pesce, G, 1991) |
| "The activity of ulcerative colitis and response to therapy was based upon daily stool diaries, sigmoidoscopy, and symptomatic response." | ( Janowitz, HD; Kornbluth, AA; Salomon, P, 1990) |
| "A male patient suffering from ulcerative colitis, presented with primary infertility due to sulphasalazine therapy." | ( Delaere, KP; Meuleman, EJ; Strijbos, WE, 1989) |
| "Patients with ulcerative colitis having a high prostaglandin E2 concentration (greater than ng/ml) determined by equilibrium dialysis of rectum, were less likely to benefit from treatment." | ( Bukhave, K; Lauritsen, K; Rask-Madsen, J; Staerk Laursen, L, 1988) |
| "We report a patient with ulcerative colitis in whom agranulocytosis was diagnosed 5 wk after the initiation of sulfasalazine therapy." | ( Blyden, GT; Demirjian, ZN; Isselbacher, KJ; Jacobson, IM; Kelsey, PB, 1985) |
| "A patient with ulcerative colitis developed eosinophilic pneumonia following treatment with Salazopyrin." | ( Bontempini, L; Braggio, P; Cazzadori, A, 1985) |
| "Patients with distal ulcerative colitis may be refractory to standard drug therapy." | ( Antonioli, DA; Barber, GB; Lee, DE; Peppercorn, MA, 1985) |
| "Chronic ulcerative colitis had been treated with oral prednisone and sulfasalazine until the second month of pregnancy and then with prednisone only." | ( Becroft, DM; Zwi, LJ, 1986) |
| "The diseases were ulcerative colitis, primary hypothyroidism and idiopathic thrombocytopenic purpura, and had been treated with L-thyroxine (50 micrograms daily) and betamethasone (0." | ( Akamizu, T; Imura, H; Inoue, D; Kasagi, K; Konishi, J; Kosugi, S; Miyamoto, M; Mori, T; Sugawa, H, 1987) |
| "Sixty-six outpatients with active ulcerative colitis who were intolerant of sulfasalazine were treated in a double-blind randomized trial." | ( Janowitz, HD; Meyers, S; Present, DH; Sachar, DB, 1987) |
| "Fifty patients with ulcerative colitis, intolerant of sulphasalazine, were treated with 500 mg olsalazine twice daily for a 3-month trial period." | ( Ireland, A; Jewell, DP, 1987) |
| "Sixty-six outpatients with active ulcerative colitis who were intolerant of sulphasalazine were treated in a double-blind randomized trial with placebo or olsalazine in daily doses of 0." | ( Janowitz, HD; Meyers, S; Present, DH; Sachar, DB, 1988) |
| "Two patients with ulcerative colitis and a past history of allergic reactions to sulfasalazine had similar reactions when treated with 5-aminosalicylic acid." | ( Fardy, JM; Lloyd, DA; Reynolds, RP, 1988) |
| "We describe a patient with ulcerative colitis and extracolonic manifestations in whom diffuse interstitial pulmonary disease developed that was responsive to glucocorticoid therapy one year after total proctocolectomy." | ( Balestra, DJ; Balestra, ST; Wasson, JH, 1988) |
| "Sixty-four patients with proven ulcerative colitis who had been maintained on sulphasalazine as their sole form of treatment for a minimum period of one year were entered into a controlled trial of sulphasalazine versus dummy tablets for a period of six months." | ( Dissanayake, AS; Truelove, SC, 1973) |
| "A woman with ulcerative colitis was treated with sulphasalazine and prednisolone." | ( Davies, D; MacFarlane, A, 1974) |
| "A survey of 458 patients treated for ulcerative colitis either medically or surgically by colectomy and the establishment of an ileostomy has provided further evidence that in Australia at least there is a significant association between ulcerative colitis and urinary calculi." | ( Bennett, RC; Hughes, ES, 1972) |
| "Sera from patients with ulcerative colitis (51), Crohn's disease (30), hypolactasia (13), untreated adult coeliac disease (11), irritable colon syndrome (24), and sera from 38 healthy control subjects were tested for antibodies to the principal cow's milk proteins-casein, alpha-lactalbumin, and beta-lactoglobulin." | ( Jewell, DP; Truelove, SC, 1972) |
| "In six patients with active ulcerative colitis on steroid therapy, the enzyme activity was similar to that observed in normal subjects." | ( Karmeli, F; Rachmilewitz, D; Sharon, P, 1984) |
| "This may prevent misdiagnosis of ulcerative colitis and unnecessary treatment with steroids." | ( Fernbach, SK; Lloyd-Still, JD, 1984) |
| "A patient with ulcerative colitis developed eosinophilic pneumonia, sinus tachycardia, skin rashes, headache and insomnia following treatment with Salazopyrin." | ( Berliner, S; Eldar, M; Kadish, U; Neeman, A; Pinkhas, J; Rousso, I; Shoenfeld, Y, 1980) |
| "Initial treatment of ulcerative colitis generally includes corticosteroids administered either rectally, orally, or parenterally." | ( Jacknowitz, AI, 1980) |
| "Thirty-four patients with ulcerative colitis completed a double-blind assessment comparing the efficacy of two weeks of treatment with nightly retention enemas containing 3 g sulphasalazine or placebo." | ( Goepel, JR; Holdsworth, CD; Palmer, KR, 1981) |
| "In eleven pregnant patients with ulcerative colitis or Crohn's disease who were treated with sulphasalazine (SASP) the serum concentrations of SASP and sulphapyridine (SP) were measured at delivery." | ( Esbjörner, E; Into-Malmberg, MB; Järnerot, G, 1981) |
| "Twelve pregnant patients with ulcerative colitis or Crohn's disease who were being treated with sulphasalazine (SASP) were studied together with their newborn, full-term babies." | ( Andersen, S; Brodersen, R; Esbjörner, E; Järnerot, G; Sandström, B, 1981) |
| "Acute attacks of ulcerative colitis should be treated without delay and corticosteroids should be used systemically and topically." | ( Jewell, DP, 1982) |
| "Seventeen patients with ulcerative colitis and three patients with Crohn's disease exhibited different side effects during sulfasalazine therapy." | ( Das, KM; Taffet, SL, 1982) |
| "A 50-yr-old woman with chronic ulcerative colitis developed severe restrictive lung disease, which progressed after total colectomy and cessation of sulfasalazine therapy." | ( Kalish, PE; McKee, AL; Pitchumoni, CS; Rajapaksa, A, 1983) |
| "Four patients with ulcerative colitis apparently limited to the rectum and distal sigmoid colon were treated by excision of the distal large bowel only, during the years 1964-1975 at St Mark's Hospital." | ( Nakano, G; Ritchie, JK; Thomson, JP, 1984) |
| "A 43-year-old female suffering from ulcerative colitis did not improve under therapy with sulfasalazine." | ( Domschke, S; Ruppin, H, 1984) |
| "A case of active ulcerative colitis and progressive sensorineural hearing loss responded to corticosteroid therapy." | ( Coker, NJ; Jenkins, HA; Weber, RS, 1984) |
| "Sixty-six patients hospitalized for ulcerative colitis were treated in a prospective, double-blind, clinical trial." | ( Goldberg, JD; Janowitz, HD; Meyers, S; Sachar, DB, 1983) |
| "Those of the ulcerative colitis patients who had been on sulphasalazine treatment continued that treatment during the trial (101 patients)." | ( Binder, V; Elsborg, L; Greibe, J; Hendriksen, C; Høj, L; Jensen, KB; Kristensen, E; Madsen, JR; Marner, B; Riis, P; Willumsen, L, 1981) |
| "Rectovaginal fistulas secondary to ulcerative colitis may be treated by ileoanal pouch anastomosis and primary repair." | ( Gordon, PH; Stein, BL, 1993) |
| "The treatment of ulcerative colitis (UC) remains empiric because of undetermined etiology and pathogenesis and incomplete understanding of the underlying immunoinflammatory events." | ( Baert, FJ; Hanauer, SB, 1995) |
| "One hundred patients with active ulcerative colitis, not reaching beyond the splenic flexure as determined by endoscopy, were treated for up to 8 weeks." | ( Danielsson, A; Graffner, H; Langholz, E; Löfberg, R; Matzen, P; Møller-Petersen, JF; Ostergaard Thomsen, O; Påhlman, L; Schiöler, R; Suhr, O, 1994) |
| "We describe a 31-year-old patient with ulcerative colitis who was successfully treated with prednisolone (PSL)." | ( Itoh, K; Jinbo, T; Kubota, K; Matsushima, T; Murakami, H; Naruse, T; Take, H; Tamura, J; Tsuchiya, J, 1994) |
| "Seventy-nine patients with distal ulcerative colitis were stratified on the basis of the extent of the disease (proctitis and proctosigmoiditis) and randomized to one of the treatment groups." | ( Brodin, U; Farup, PG; Halvorsen, FA; Hovde, O; Raknerud, N, 1995) |
| "In the majority of patients with severe ulcerative colitis, circulating concentrations of NOX are increased at presentation and fall promptly during parenteral steroid therapy, irrespective of clinical outcome." | ( Cornelissen, PL; Jewell, DP; Rees, DC; Satsangi, J; Travis, SP; White, J, 1995) |
| "Five children with ulcerative colitis for whom surgery was recommended were treated with cyclosporine." | ( Benkov, KJ; Janowitz, HD; LeLeiko, NS; Rosh, JR; Schwersenz, AH, 1994) |
| "In Crohn's disease as well as in ulcerative colitis steroids are of major importance in the treatment of active disease." | ( Schölmerich, J, 1995) |
| "A patient with ulcerative colitis refractory to standard therapy was treated with heparin for a deep vein thrombosis." | ( Annis, P; Doyle, CT; Gaffney, A; Gaffney, PR; Hayes, DP; Hogan, J, 1995) |
| "Nine patients with distal ulcerative colitis refractory to standard therapy were treated with intrarectal instillation of a sodium butyrate solution and 5-ASA." | ( Caprilli, R; Cittadini, M; Torsoli, A; Vernia, P, 1995) |
| "We treated 80 patients with ulcerative colitis in remission with either transdermal nicotine or placebo patches for six months in a randomized, double-blind study." | ( Feyerabend, C; Mani, V; Newcombe, RG; Rhodes, J; Russell, MA; Thomas, GA; Williams, GT, 1995) |
| "We report the case of a patient with ulcerative colitis and autoimmune hemolytic anemia, that improved with steroid therapy, and during the follow-up showed analytical changes of iron deficiency anemia and anemia of chronic disorders." | ( Navascués, CA; Riestra, S; Rodrigo, L; Rodríguez, M; San Román, FS; Suárez, A, 1994) |
| "We treated 72 patients with active ulcerative colitis with either transdermal nicotine patches or placebo patches for six weeks in a randomized, double-blind study." | ( Feyerabend, C; Ganesh, S; Mani, V; Morris, JS; Newcombe, RG; Pullan, RD; Rhodes, J; Russell, MA; Thomas, GA; Williams, GT, 1994) |
| "In an trial 12 patients with distal ulcerative colitis unresponsive to treatment with topical and oral corticosteroids, 5-aminosalicylic acid, and oral immunosuppressive therapy together with 1 patient with 'pouchitis' unresponsive to repeated courses of antibiotics, topical corticosteroids, and oral mesalazine received 250 mg cyclosporin administered daily as a retention enema." | ( Campbell, A; Dalton, HR; Jewell, DP; Merrett, MN; Winter, TA, 1993) |
| "Treatment of acute attacks of ulcerative colitis in 89 patients with doses of prednisolone above or equal to 40 mg resulted in an overall remission in 67%." | ( Kjeldsen, J, 1993) |
| "Six severe and 7 moderately severe ulcerative colitis patients were treated by pulsed steroid therapy." | ( Kitano, A; Kobayashi, K; Matsumoto, T; Nakamura, S; Okabe, H; Oshitani, N, 1993) |
| "Of 12 patients with active ulcerative colitis (UC), 4 patients were without treatment, 4 were on prednisone and 4 on mesalazine." | ( Agostini, D; Boirivant, M; Corsi, A; D'Ambrosio, C; Letizia, C; Pallone, F; Scavo, D, 1993) |
| "Severely ill patients with ulcerative colitis are usually treated with parenteral corticoids." | ( Peppercorn, MA, 1993) |
| "Thirty patients had coexisting ulcerative colitis, including three who had previously undergone colectomy and one who discontinued treatment after three months." | ( Larusso, NF; Sandborn, WJ; Tremaine, WJ; Wiesner, RH, 1993) |
| "We report two patients with ulcerative colitis who developed PCP during high-dose corticosteroid therapy, and review the literature regarding non-AIDS PCP." | ( Bernstein, CN; Block, E; Kolodny, M; Shanahan, F, 1993) |
| "Sulphasalazine treatment in ulcerative colitis causes only minor disturbance to the populations of bacteria colonizing the colorectal mucosa." | ( Gent, AE; Grace, RH; Hartley, MG; Hellier, MD; Hudson, MJ; Swarbrick, ET, 1996) |
| "Twenty children with active ulcerative colitis were assessed before and after 8 weeks of medical therapy with 5-aminosalicylic acid (5-ASA) derivatives and corticosteroids." | ( Beattie, RM; Domizio, P; Nicholls, SW; Walker-Smith, JA; Williams, CB, 1996) |
| "The activity score of ulcerative colitis diminished significantly after 12 weeks of treatment, but five patients dropped out of the study." | ( Boer, RO; Lourens, J; Sindram, JW; Tuynman, HA; van Bodegraven, AA, 1996) |
| "To determine the long term outcome of ulcerative colitis in patients treated with 6-MP." | ( Bodian, C; George, J; Pou, R; Present, DH; Rubin, PH, 1996) |
| "The charts of 105 chronic refractory ulcerative colitis patients treated with 6-MP from 1973-1992 were reviewed." | ( Bodian, C; George, J; Pou, R; Present, DH; Rubin, PH, 1996) |
| "Distal ulcerative colitis can be treated with oral or rectal mesalazine, or both." | ( Daniels, S; Grace, RH; Jewell, DP; Keighley, MR; Kingston, RD; Lee, FI; Mani, V; Patterson, J; Record, CO; Smith, K, 1996) |
| "Sixty-one patients with active ulcerative colitis were treated with either transdermal nicotine patches or 15 mg prednisolone for 6 weeks in a randomized, double-blind study." | ( Feyerabend, C; Mani, V; Newcombe, RG; Ragunath, K; Rhodes, J; Russell, MA; Thomas, GA; Williams, GT, 1996) |
| "Periods of chronic ulcerative colitis in mice were induced by three repeated administrations of 3% dextran sulphate sodium subsequent to a single azoxymethane pretreatment, to give conditions similar to the clinically observed active and remission phases." | ( Kajiura, K; Kanno, J; Ohkusa, T; Okayasu, I; Sakamoto, S, 1996) |
| "In patients with ulcerative colitis receiving maintenance 5-ASA therapy there was greater absorption and less acetylation of 5-ASA from mesalazine (Asacol) compared with sulphasalazine or olsalazine, but no evidence from this study that this resulted in increased nephrotoxicity." | ( Campbell, BJ; Dwarakanath, AD; Morris, AI; Rhodes, JM; Stevenson, A; Stretch, GL; Yaqoob, M, 1996) |
| "Patients with ulcerative colitis who were not on long-term sulphasalazine or 5-aminosalicylic acid therapy (either because a doctor stopped it or they did not comply with treatment) were significantly more likely to develop colorectal cancer than their compliant counterparts." | ( Jayanthi, V; Mac Kay, H; Mayberry, JF; Moody, GA; Probert, CS, 1996) |
| "A 73 year-old woman with ulcerative colitis developed skin rashes after long-standing sulphasalazine treatment." | ( Gunnarsson, I; Lindblad, S; Pettersson, E; Ringertz, B, 1997) |
| "We tried to produce a new ulcerative colitis model in rats by topical administration of sulfhydryl blockers." | ( Sato, F; Satoh, H; Szabo, S; Takami, K, 1997) |
| "The lethality of the severe ulcerative colitis has been markedly reduced in the last decades by drug and surgical therapy." | ( Rückert, Y, 1997) |
| "Topical nicotine therapy for ulcerative colitis may have a place in future management, but controlled studies are needed." | ( Evans, BK; Feyerabend, C; Green, JT; Rhodes, J; Rhodes, P; Russell, MA; Sandborn, WJ; Thomas, GA; Williams, GT, 1997) |
| "Effective medical treatment of ulcerative colitis is available." | ( Schölmerich, J, 1997) |
| "Refractory ulcerative colitis is best treated surgically." | ( Kam, L, 1998) |
| "The treatment of ulcerative colitis and Crohn's disease shares certain common principles." | ( Beglinger, C, 1997) |
| "Topical therapy for the treatment of ulcerative colitis is also discussed." | ( Ragnarsson, G; Ulmius, J; Wikberg, M, 1997) |
| "A 40-year-old white man with ulcerative colitis, treated with chronic mesalamine and occasional steroids, was admitted to the hospital with a 3-day history of fever, nausea, vomiting, and a rash." | ( Garey, KW; Rainish, MC; Streetman, DS, 1998) |
| "A case of severe ulcerative colitis refractory to steroid therapy is reported." | ( Baptista, C; Canena, J; Dias, R; Leitão, J; Penedo, J; Pinto, A; Quina, M; Ramos, M; Reis, J; Santos, AM; Turpin, S, 1998) |
| "Twenty-seven patients with active ulcerative colitis and 42 with active Crohn's disease treated with glucocorticoids were studied." | ( Brandslund, I; Kjeldsen, J; Lassen, JF; Schaffalitzky de Muckadell, OB, 1998) |
| "We report a case of steroid-refractory ulcerative colitis, treated with cyclosporine, in a 38-year-old woman with a 13-year history of ulcerative colitis." | ( Hassan, M; Kashimura, H; Matsumaru, K; Muto, H; Nakahara, A; Shibahara, K; Suzuki, K; Tanaka, N; Yanaka, A, 1998) |
| "Patients with ulcerative colitis undergoing IAA surgery were randomly assigned to double-blind treatment with placebo (n=12) or 6 IU GH twice daily (n=12) from 2 d before to 7 d after the operation." | ( Jensen, MB; Kissmeyer-Nielsen, P; Laurberg, S, 1998) |
| "Drugs for the treatment of ulcerative colitis are sulphapyridine, 5-aminosalicylic acid, prednisolone, betamethasone and immunosuppressive drugs." | ( Asakura, H, 1998) |
| "In this study 7 patients with severe ulcerative colitis and 4 patients with active Crohn's disease unresponsive to prednisone were treated with high dose intravenous cyclosporine." | ( Dejaco, C; Gangl, A; Gasché, C; Moser, G; Novacek, G; Reinisch, W; Tillinger, W; Vogelsang, H, 1998) |
| "Preexisting ulcerative colitis often has an aggressive course, while de novo ulcerative colitis may develop in patients transplanted for primary sclerosing cholangitis and treated without long term steroids." | ( Burroughs, AK; Davidson, B; Hamilton, M; Mistry, PK; Papatheodoridis, GV; Rolles, K, 1998) |
| "A total of 105 patients with ulcerative colitis who were in remission were randomized into groups to receive oral treatment with Plantago ovata seeds (10 g b." | ( Domínguez-Abascal, F; Fernández-Bañares, F; García-Pugés, A; Gassull, MA; Giné, JJ; Gomollón, F; González-Huix, F; González-Lara, V; Hinojosa, J; Martínez-Salmerón, JF; Moles, J; Navarro, E; Riera, J; Sánchez-Lombraña, JL, 1999) |
| "Fifteen patients with ulcerative colitis were treated with olsalazine or mesalazine, each for 7 days in an open, randomized, crossover design study." | ( Florholmen, J; Støa-Birketvedt, G, 1999) |
| "She had been suffering ulcerative colitis and administered salazosulphapyridine and predonisolone from 17-year-old." | ( Kamijo, T; Nagase, Y; Yanagisawa, R, 1999) |
| "All steroid-refractory severe ulcerative colitis (UC) patients treated with IV CSA from 1991 to 1995 were identified by using the university's IBD database, with additional information from patient charts and physician files." | ( Cohen, RD; Hanauer, SB; Stein, R, 1999) |
| "We report a rare case of ulcerative colitis (UC) associated with methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa infections in multiple organs, and with compressive fracture from osteoporosis after the administration of high-dose prednisolone and azathioprine." | ( Abo, Y; Kawamura, YJ; Masaki, T; Matsuda, K; Muto, T; Uchida, H; Watanabe, T, 1999) |
| "Up to 29% of patients with severe ulcerative colitis (UC) fail to respond to steroid treatment and require surgery." | ( Dayan, CM; Haslam, N; Hearing, SD; Norman, M; Probert, CS, 1999) |
| "At present, it is embarrassing that ulcerative colitis (UC), Crohn's (CR) and interstitial cystitis (IC) are the cause of a great deal of morbidity and occasionally mortality, yet after intensive research, the etiology and effective treatment eludes us." | ( Russell, AL, 1999) |
| "Twenty patients with ulcerative colitis, intolerant or allergic to 5-ASA, have been treated with a new probiotic preparation (VSL#3, CSL, Milan, Italy) containing 5x10(11) cells/g of 3 strains of bifidobacteria, 4 strains of lactobacilli and 1 strain of Streptococcus salivarius ssp." | ( Brigidi, P; Campieri, M; Gionchetti, P; Johansson, R; Matteuzzi, D; Rizzello, F; Venturi, A; Zucconi, E, 1999) |
| "Selection of treatment for ulcerative colitis is based on the definition of clinical severity." | ( Fujinuma, S; Nakajima, S; Sakai, K; Sakai, Y, 1999) |
| "Therapeutic trials in left-sided ulcerative colitis (L-UC) and ulcerative proctitis (UP) have lacked control for medication type, dose, delivery, and duration of therapy." | ( Cohen, RD; Hanauer, SB; Thisted, RA; Woseth, DM, 2000) |
| "118 cases of ulcerative colitis were treated by integration of traditional Chinese and Western medicine." | ( Chen, Q; Zhang, H, 1999) |
| "The treatment of ulcerative colitis (UC) with 5-aminosalicylic acid (5-ASA) does not have the same therapeutic effect in all patients." | ( Caprilli, R; Frieri, G; Giacomelli, R; Palumbo, G; Pantaleoni, G; Passacantando, A; Pimpo, M, 2000) |
| "We report a case of refractory ulcerative colitis treated with tacrolimus." | ( Iwadare, JI; Komeno, Y; Kondo, K; Matsuhashi, N; Muto, T; Nagawa, H; Nakajima, A; Ohnishi, S; Omata, M; Suzuki, A; Usui, Y; Watanabe, K; Watanabe, T, 2000) |
| "About one-third of patients with severe ulcerative colitis do not respond to conventional therapy and require urgent colectomy." | ( Avidan, B; Avni, Y; Bujanover, Y; Fireman, Z; Leichtman, G; Maor, Y; Moskowitz, M; Naftali, T; Novis, B; Pomeranz, I; Shapiro, R, 2000) |
| "Important observations in ulcerative colitis (UC) over the past year include evidence of a protective effect of 5-aminosalicylic acid (5-ASA) with respect to colorectal cancer, negative results from a study for heparin monotherapy, and results from a comparison of mycophenolate mofetil versus azathioprine as maintenance therapy." | ( Baert, FJ; Rutgeerts, PJ, 2000) |
| "Three patients with steroid-refractory ulcerative colitis and two patients with steroid refractory Crohn's disease who failed monotherapy with subcutaneous methotrexate 25 mg/week for 16 weeks were treated with the combination of methotrexate and low-dose oral cyclosporine (3 mg/kg/day) for an additional 16 weeks." | ( Egan, LJ; Lipsky, JJ; Mays, DC; Sandborn, WJ; Tremaine, WJ, 2000) |
| "The association with chronic ulcerative colitis is well known, but the diagnosis may be complicated by early administration of systemic steroids." | ( Breuer, C; Kapp, A; Kiehl, P; Petering, H; Werfel, T, 2001) |
| "In cases of the nonspecific ulcerative colitis and Crohn's disease of colon the thyroid gland insufficiency occurs in variant of the thriiodinethyronine low contents syndrome, causing the necessity of the substitution therapy conduction in postoperative period." | ( Volkov, VI, 2000) |
| "We randomly assigned 203 patients with ulcerative colitis who were undergoing hospital follow-up to receive patient-centred self-management training and follow-up on request (intervention group), or normal treatment and follow-up (control group)." | ( Roberts, C; Robinson, A; Thompson, DG; Wilkin, D, 2001) |
| "Self-management of ulcerative colitis accelerates treatment provision and reduces doctor visits, and does not increase morbidity." | ( Roberts, C; Robinson, A; Thompson, DG; Wilkin, D, 2001) |
| "Approximately a third of acutely ill ulcerative colitis patients refractory to standard treatment with high-dose glucocorticoids will benefit from intravenous cyclosporine in the longer term." | ( Kjeldsen, J; Knudsen, T; Wilson, BV, 2001) |
| "Treatment of moderate to severe ulcerative colitis with high-dose heparin and low-molecular-weight heparin was reported." | ( Alexandrowitz, A; Arber, N; Brazowski, E; Dotan, I; Hallak, A; Halpern, Z; Hershkoviz, R; Knaani, Y; Santo, M, 2001) |
| "Patients with active distal ulcerative colitis, diagnosed according to standardized criteria, were treated for 4 weeks." | ( Gertz, B; Malchow, H, 2002) |
| "Azathioprine is effective treatment for ulcerative colitis and Crohn's disease." | ( Fraser, AG; Jewell, DP; Orchard, TR, 2002) |
| "Distal ulcerative colitis usually responds to treatment with rectal mesalamine, but the management of refractory cases is poorly defined." | ( Frego, R; Guslandi, M; Testoni, PA; Viale, E, 2002) |
| "Thirty patients with left-sided ulcerative colitis unresponsive to treatment with a mesalamine 4 g enema at bedtime were randomly allocated to additional therapy with either transdermal nicotine 15 mg daily or oral mesalamine 800 mg tid for four weeks." | ( Frego, R; Guslandi, M; Testoni, PA; Viale, E, 2002) |
| "Twelve patients with ulcerative colitis were administered rifaximin 1800 mg/day in 3 treatment periods of 10 days, each followed by 25 days of wash-out." | ( Bozzolasco, M; Brigidi, P; Matteuzzi, D; Rizzello, F; Swennen, E, 2002) |
| "Severe ulcerative colitis is conventionally treated with parenteral corticosteroids followed by oral corticosteroids." | ( Awasthi, G; Midha, V; Sood, A; Sood, N, 2002) |
| "A series of 13 patients with severe ulcerative colitis, refractory to therapy with methyl-prednisolone, 60 mg daily for seven or more days, were treated with a single intravenous infusion of Infliximab 5 mg/kg." | ( Cosintino, R; Daperno, M; Kohn, A; Pera, A; Prantera, C; Sostegni, R, 2002) |
| "It describes the treatment of ulcerative colitis according to the different groups of patients and the degree of activity." | ( Nagy, F, 2002) |
| "Traditional therapy for ulcerative colitis with nonspecific anti-inflammatories remains our gold standard." | ( Kane, SV; Tuvlin, JA, 2003) |
| "The treatment of distal ulcerative colitis, refractory to conventional 5-ASA/steroid treatment, is still a matter of debate." | ( Annese, V; Bresci, G; Caprilli, R; d'Albasio, G; D'Incà, R; Giaccari, S; Ingrosso, M; Mansi, C; Riegler, G; Valpiani, D; Vernia, P, 2003) |
| "A 50 years old male with a diagnosis of ulcerative colitis treated with mesalazine, developed after 2 months of treatment, cough, fever and progressive dyspnea." | ( Brockmann, P; Cofré, C; Errázuriz, I; González, S; Pérez, C, 2003) |
| "The long-term complications of ulcerative colitis include steroid-induced osteoporosis and anemia and should be treated adequately." | ( Kullak-Ublick, GA; Rammert, Ch, 2003) |
| "In humans, ulcerative colitis is normally treated with aminosalicylates (ASAs) and corticosteroids (CSs) to reduce inflammation." | ( Brubaker, PL; L'Heureux, MC, 2003) |
| "Patients diagnosed as ulcerative colitis (UC) and treated with leukocyte apheresis were studied." | ( Hirayama, A; Hirayama, K; Ishizu, T; Kobayashi, M; Koyama, A; Nagase, S; Taru, Y; Ueda, A; Yoh, K, 2003) |
| "Steroid refractory ulcerative colitis is most commonly treated with intravenous ciclosporin to avoid colectomy." | ( Hinterleitner, TA; Högenauer, C; Petritsch, W; Wenzl, HH, 2003) |
| "Cyclosporin-A therapy in severe ulcerative colitis that is refractory to steroids, provides initial remission in 80% of patients and allows 40% to retain their colon for 1 year." | ( Besisik, F; Boztas, G; Cakaloglu, Y; Danalioglu, A; Demir, K; Durakoglu, Z; Karaca, C; Kaymakoglu, S; Mungan, Z; Okyen, A, 2003) |
| "A 43-year-old female with ulcerative colitis treated by proctocolectomy and ileal pouch--anal anastomosis developed acute pouchitis." | ( Abdelrazeq, AS; Leveson, SH; Lund, JN, 2004) |
| "The aetiology of bone loss in ulcerative colitis is multifactorial, but corticosteroid treatment is an important risk factor." | ( Darlow, SJ; Mandal, A; Mayberry, JF; Pick, B; Robinson, RJ; Thomas, T, 2004) |
| "no symptoms of ulcerative colitis), and expressed as a percentage of the patients randomized (intention to treat analysis)." | ( Macdonald, JK; McDonald, JW; McGrath, J, 2004) |
| "From 1986 through 2000, ulcerative colitis was diagnosed and treated in 886 patients at Kitasato University East Hospital." | ( Igarashi, M; Katsumata, T; Kobayashi, K; Mitomi, H; Okayasu, I; Otani, Y; Sada, M; Saigenji, K; Yoshizawa, S, 2004) |
| "Patients with ulcerative colitis treated with oral methotrexate at the inflammatory bowel disease clinics of Oxford and Wycombe General Hospital, UK, were evaluated." | ( Cummings, JR; Gorard, DA; Herrlinger, KR; Jewell, DP; McIntyre, AS; Travis, SP, 2005) |
| "Eighteen consecutive ulcerative colitis patients on continuous oral 5-ASA treatment (2." | ( Caprilli, R; Chiaramonte, M; Corrao, G; Frieri, G; Galletti, B; Latella, G; Palumbo, G; Pimpo, M, 2005) |
| "Patients with ulcerative colitis were divided into five groups: a) no history of pouchitis (pouch for at least 2 years; n = 8); b) past episode(s) of pouchitis but no active disease for the previous year (n = 9); c) pouchitis in the past year but presently inactive (n = 9); d) ongoing antibiotic treatment (metronidazole or ciprofloxacin) for pouchitis (n = 11); e) currently suffering from pouchitis (n = 8)." | ( Furne, JK; Levitt, MD; Madoff, RD; Ohge, H; Rothenberger, DA; Springfield, J, 2005) |
| "Therapy for active ulcerative colitis (UC) usually involves rectal formulations of corticosteroids (CS), which are characterized by the risk of systemic steroid-related adverse effects." | ( Annese, V; Balzano, A; Campieri, M; D'Arienzo, A; Gionchetti, P; Iaquinto, G; Lecis, PE; Maieron, R; Manguso, F; Rizzello, F; Valpiani, D; Varoli, G, 2005) |
| "Steroid-dependent Crohn's disease and ulcerative colitis patients receiving either azathioprine or not (treated later with a daily dose of 2." | ( Bessard, G; Bonaz, B; Chartier, A; Faucheron, JL; Hardy, G; Helluwaert, F; Phelip, JM; Roblin, X; Serre-Debeauvais, F, 2005) |
| "Twenty patients with ulcerative colitis were randomly assigned into the antibiotic treatment group (amoxicillin, tetracycline and metronidazole for 2 weeks) and no-antibiotics group." | ( Benno, Y; Hayashi, H; Hirai, S; Hojo, M; Kobayashi, O; Miwa, H; Nomura, T; Ogihara, T; Ohkusa, T; Okayasu, I; Sakamoto, M; Sato, N; Takei, Y; Terai, T; Yoshida, T, 2005) |
| "Mesalazine as maintenance therapy in ulcerative colitis is used worldwide and has been proven to be effective." | ( Consolazio, A; Crispino, P; Iacopini, F; Marcheggiano, A; Paoluzi, OA; Paoluzi, P; Pica, R; Rivera, M, 2005) |
| "A total of 156 patients with ulcerative colitis in remission were randomly treated for 1 year with 2." | ( Consolazio, A; Crispino, P; Iacopini, F; Marcheggiano, A; Paoluzi, OA; Paoluzi, P; Pica, R; Rivera, M, 2005) |
| "Treatment of ulcerative colitis has changed little in recent years, except for our improved ability to deliver mesalazine to the large bowel via the recent availability of several oral and rectal preparations." | ( Gibson, PR; Iser, J, 2005) |
| "Guidelines for treatment of ulcerative colitis in children have been created by the working group of the Japanese Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Japanese Society for Pediatric Inflammatory Bowel Disease." | ( Tomomasa, T, 2005) |
| "Current treatment of ulcerative colitis is imperfect." | ( Fitzgerald, AJ; Ghosh, S; Mahmood, A; Melley, L; Playford, RJ, 2005) |
| "Colonic biopsies from ulcerative colitis were treated with 0, 1, 5, and 10 microM DATS for 24 hr." | ( Bai, AP; Hu, RW; Ouyang, Q, 2005) |
| "Since ulcerative colitis is associated with an increased risk in developing colon carcinoma, medical therapy as well as endoscopic surveillance are fundamental in the prevention of carcinoma." | ( Siegmund, B; Zeitz, M, 2005) |
| "Patients with moderately active ulcerative colitis treated with 4." | ( Ajayi, F; Hanauer, SB; Katz, S; Kornbluth, A; Regalli, G; Safdi, M; Sandborn, WJ; Smith-Hall, N; Woogen, S; Yeh, C, 2005) |
| "She had been diagnosed and treated for ulcerative colitis for four years." | ( Hirabayashi, K; Katayama, Y; Katsura, K; Nagao, T; Nomoto, T; Seta, T; Yokochi, M, 2006) |
| "First-line therapy for ulcerative colitis is 5-aminosalicylic acid, which suffers from poor patient adherence outside the clinical trial setting." | ( Kane, SV, 2006) |
| "We report on a 30-year-old male with ulcerative colitis who developed a spontaneous gas gangrene in the right limb, the gluteal muscles and the retroperitoneal region under immunosuppressive therapy." | ( Freitag, M; Jackisch, T; Ludwig, K, 2006) |
| "One hundred and sixteen cases of ulcerative colitis were randomly divided into a treatment group and a control group." | ( Li, GP; Li, HJ; Li, HY, 2006) |
| "Thirty-four adult patients with active ulcerative colitis were consecutively included in a prospective, randomized, comparative study, and were treated for 12 weeks." | ( Evgenidis, N; Giouleme, O; Nikolaidis, N; Papageorgiou, A; Papaioannou, G; Patsiaoura, K; Vassiliadis, T; Zezos, P, 2006) |
| "Interestingly, treatment of ulcerative colitis with mesalazine, which displays few side effects during long-term treatment, is associated with a reduced incidence of colorectal cancer, but its molecular mechanism is not known." | ( Bos, CL; Diks, SH; Hardwick, JC; Peppelenbosch, MP; Richel, DJ; Walburg, KV, 2006) |
| "Patients with steroid-refractory ulcerative colitis face a difficult treatment decision between colectomy and therapy with infliximab or cyclosporine." | ( Arseneau, KO; Bickston, SJ; Cominelli, F; Connors, AF; Foley, E; Onken, J; Provenzale, DT; Sultan, S, 2006) |
| "In patients with moderate to severe ulcerative colitis whose disease was refractory to conventional treatment using corticosteroids and/or immunosuppressive agents, infliximab (three intravenous infusions at 0, 2, and 6 weeks) was more effective than placebo in inducing clinical remission (Relative Risk (RR) 3." | ( Akobeng, AK; Lawson, MM; Thomas, AG, 2006) |
| "In patients with moderate to severe ulcerative colitis whose disease is refractory to conventional treatment using corticosteroids and/or immunosuppressive agents, infliximab is effective in inducing clinical remission, inducing clinical response, promoting mucosal healing, and reducing the need for colectomy at least in the short term." | ( Akobeng, AK; Lawson, MM; Thomas, AG, 2006) |
| "She had ulcerative colitis when she was 16 and received medical treatment." | ( Araki, A; Chin, S; Itsui, Y; Kanai, T; Kawamura, T; Kubota, D; Matsumoto, T; Miyata, T; Ohoka, S; Okada, E; Sakamoto, N; Tsuchiya, K; Watanabe, M, 2006) |
| "We report a case of severe ulcerative colitis complicated with primary diabetes mellitus that was effectively treated with oral tacrolimus." | ( Hirai, F; Matsui, T; Wada, Y; Yano, Y, 2006) |
| "Patients with mild-moderate ulcerative colitis who do not improve within 2 weeks of high-dose 5-aminosalicylic acid should have treatment augmented by oral steroids." | ( Travis, SP, 2006) |
| "After 2 years on ulcerative colitis treatment, he presented with metastatic gastrointestinal tumor, liver and peritoneal spread, and a pelvic mass." | ( Al-Kindy, S; Al-Moundhri, MS; Al-Thahli, K; Rao, L; Salam, J, 2006) |
| "One hundred fifty six patients with ulcerative colitis who were treated with AZA from January 1995 to December 2003 were reviewed." | ( Bansal, M; Midha, V; Sood, A; Sood, N, 2006) |
| "Forty patients with acute ulcerative colitis were randomly divided in two groups of 20 subjects each: one group was treated with five sessions of granulocytapheresis, the other one with methylprednisolone for 5 weeks." | ( Bresci, G; Capria, A; Mazzoni, A; Parisi, G; Scatena, F, 2007) |
| "Clinical remission of ulcerative colitis was obtained by prednisolone administration." | ( Ekonomou, IA; Giannoulis, EK; Giannoulis, KE; Savopoulos, CG; Tsesmeli, NE; Vretou, EE, 2007) |
| "A 38 year-old man with ulcerative colitis recently treated with balsalazide was admitted with chest pain." | ( Austin, D; Hogg, KJ; Jamieson, N; Robertson, E, 2008) |
| "Maintenance treatment in ulcerative colitis should be as convenient as possible, to increase the chance of compliance." | ( Barrett, K; Joseph, R; Kamm, MA; Lees, K; Lichtenstein, GR; Sandborn, WJ; Schreiber, S, 2008) |
| "LVA therapy is able to suppress chronic ulcerative colitis in experimental model." | ( Eshraghi, S; Eslami, MB; Khodadadi, A; Mirshafiey, A; Razavi, A, 2008) |
| "Significant number of patients with ulcerative colitis (UC) fail to comply with treatment." | ( Ghosh, S; Hawthorne, AB; Rubin, G, 2008) |
| "A 28 year-old man with ulcerative colitis treated for 10 years with azathioprine (AZA) returned from Central Asia with fever, swollen lymph glands, hepatosplenomegaly, and pancytopenia." | ( Albrectsen, JM; Andersen, O; Kiszka-Kanowitz, M; Kofoed, K, 2008) |
| "Some patients with ulcerative colitis (UC) require immunosuppressants as maintenance therapy." | ( Chande, N; Gregor, JC; Lau, A; Ponich, T, 2008) |
| "In children with severe ulcerative colitis IFX is a valuable treatment for inducing remission, avoiding emergency colectomy; retreatment may be offered to maintain remission." | ( Cottone, M; Cucchiara, S; de'Angelis, GL; Federici, T; Fontana, M; Lombardi, G; Romeo, E; Rutigliano, V; Viola, F, 2008) |
| "Many patients with ulcerative colitis (UC) respond to mesalamine therapy within 8 weeks." | ( Barrett, K; Joseph, R; Kamm, MA; Lees, K; Lichtenstein, GR; Sandborn, WJ; Schreiber, S, 2009) |
| "Nearly 25% of patients with ulcerative colitis (UC) requiring steroids therapy become steroid-dependent after 1 yr, and virtually all develop steroid-related adverse events." | ( Andriulli, A; Annese, V; Bossa, F; Dallapiccola, B; Damonte, G; De Santo, E; Latiano, A; Magnani, M; Palmieri, O; Rossi, L; Serafini, S, 2008) |
| "To describe the long-term prognosis of ulcerative colitis (UC) and to establish whether a correlation exists between the different anatomic locations of the disease and the risk of relapse in a homogeneous cohort of patients with UC in clinical remission, all treated with fixed doses of oral mesalamine from the date of enrollment to the appearance of the first relapse." | ( Bresci, G; Capria, A; Parisi, G, 2008) |
| "Thirty-nine patients with ulcerative colitis and treated with glucocorticoids were randomized to receive alendronate (5 mg/day) or alfacalcidol (1 microg/day) daily for 12 months." | ( Harada, K; Kitazaki, S; Kuwaki, K; Masuda, J; Mitsuyama, K; Sata, M; Sugiyama, G; Takedatsu, H; Tsuruta, O; Yamasaki, H, 2009) |
| "Strict clinical remission endpoints in ulcerative colitis (UC) trials produce low remission rates and do not reflect the good outcomes of UC therapy." | ( Higgins, PD; Rangwalla, SC; Waljee, AK, 2009) |
| "Two hundred sixty two patients with ulcerative colitis were randomly divided into four groups: the patients in traditional Chinese medicine group were fed with changpikang, the patients in ear acupoint group were pasted and pressed spleen, large intestine, sympathesis, subcortex; the patients in medicine and acupoint group were taken with Changpikang and ear acupoint; the patients in treatment group were treated by taking sulfasalazine, with a treatment course of four weeks." | ( Du, YR; Li, DG; Liu, QG; Zhang, W; Zhu, F, 2008) |
| "A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment." | ( Aoyama, R; Imai, H; Kitagawa, W; Miura, N; Nishikawa, K; Yamada, H, 2009) |
| "Crohn's disease (CD) or ulcerative colitis/IBD unclassified (UC/IBDU) patients intolerant or refractory to conventional medical therapy received MMF (500-2000 mg bid)." | ( Lawrance, IC; Tan, T, 2009) |
| "A 48-year-old female with severe ulcerative colitis refractory to conventional therapy was referred to our facility for management." | ( Cury, DB; Cury, Mde S; Elias, GV; Mizsputen, SJ, 2009) |
| "Patients with ulcerative colitis given prolonged-release oral mesalamine 2 g once daily had better remission rates, acceptability, and self-reported adherence to therapy compared with patients given oral mesalamine 1 g twice daily." | ( Adamek, H; Bhatt, A; Bokemeyer, B; Börner, N; Dietel, P; Dignass, AU; Klugmann, T; Mross, M; Pool, MO; Silvennoinen, J; Stijnen, T; Tan, G; Veerman, H; Vermeire, S; Vinter-Jensen, L, 2009) |
| "The treatment of severe ulcerative colitis (UC) flares includes measures such as hospitalization and intravenous steroids." | ( Casellas Jordá, F; Huamán Ríos, JW; Malagelada Benaprés, JR, 2009) |
| "Fifteen ulcerative colitis patients who did not respond to high-doses of corticosteroids were treated with cyclosporin A by continuous intravenous infusion at 4mg/kg/day for 20 days." | ( Ando, T; El-Omar, EM; Goto, H; Hasegawa, M; Ina, K; Ishiguro, K; Miyahara, R; Miyake, N; Nakamura, M; Niwa, Y; Ohmiya, N; Shimada, M; Watanabe, O, 2009) |
| "Treatment of patients with ulcerative colitis (UC) has traditionally focused on improving symptoms, with the main objective of inducing and maintaining symptomatic remission." | ( Lichtenstein, GR; Rutgeerts, P, 2010) |
| "Crohn's disease and ulcerative colitis are chronic inflammatory disease of the intestine,which frequently require surgery for complications or failure of medical therapy." | ( Bosques-Padilla, FJ; Galindo-Marines, SL; Yamamoto-Farusho, JK, 2008) |
| "Fourteen patients with active distal ulcerative colitis were randomized to either rosiglitazone (4 mg) or mesalazine (1 g) enema treatment once daily for 14 days." | ( Brynskov, J; Pedersen, G, 2010) |
| "The treatment of ulcerative colitis (inflammatory bowel disease, IBD) has been achieved by using colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride." | ( Dubey, R; Jain, SK; Omrey, P; Vyas, SP, 2010) |
| "Therapy of uncomplicated nonspecific ulcerative colitis with artrofoon effectively reduces the duration and number of relapses." | ( Osadchuk, AM; Osadchuk, MA, 2009) |
| "Mesalazine therapy for ulcerative colitis has been reported to be effective and safe." | ( Allegri, MP; Carli, T; Chigiotti, S; Cresti, A; Migliorini, MG; Nencioni, C; Perari, MG; Riccardi, MP; Ricciardi, B; Sposato, B; Toti, M, 2010) |
| "Therapy for active left-sided ulcerative colitis usually involves topical application of mesalazine (mesalamine) or budesonide." | ( Hartmann, F; Stein, J, 2010) |
| "The pathogenesis and treatment of ulcerative colitis remain poorly understood." | ( Altıntas, A; Caliskan-Ak, E; Cetinel, S; Genc, Z; Isik, F; Pisiriciler, R; Sener, G; Tunali Akbay, T; Yarat, A, 2011) |
| "Optimizing treatment goals in ulcerative colitis requires recognizing the needs of patients." | ( Elkjaer, M; Marteau, P; Michetti, P; Munkholm, P; Probert, CS, 2010) |
| "A total of 71 patients with severe ulcerative colitis were treated with IV CSA." | ( Cheifetz, AS; Garud, S; Goldstein, E; Malter, L; Moss, AC; Present, DH; Stern, J, 2011) |
| "CSA is an effective therapy for severe ulcerative colitis." | ( Cheifetz, AS; Garud, S; Goldstein, E; Malter, L; Moss, AC; Present, DH; Stern, J, 2011) |
| "HIF isolated from CD, ulcerative colitis (UC), and normal intestine were treated with tocotrienol-rich fraction (TRF) from palm oil." | ( Delgado, S; España, C; Llach, J; Luna, J; Masamunt, MC; Mora, R; Rickmann, M; Sans, M; Vaquero, E, 2011) |
| "He was diagnosed to have ulcerative colitis 2 years ago and had been treated with sulfasalazine." | ( Cheung, DY; Hong, SI; Kim, GM; Kim, JI; Kim, JK; Kim, YC; Lee, HS; Park, SH, 2010) |
| "Primary endpoint was the ulcerative colitis-disease activity index (UC-DAI) score before and after 8 weeks of treatment." | ( Hibi, T; Hiwatashi, N; Mitsuyama, K; Munakata, A; Suzuki, Y, 2011) |
| "Acute severe ulcerative colitis is a potentially lethal condition that requires a pro-active approach with either effective medical treatment or timely colectomy." | ( Rutgeerts, P; Van Assche, G; Vermeire, S, 2011) |
| "The natural history of ulcerative colitis requires continuous monitoring of medical treatment via frequent outpatient visits." | ( Avnstrøm, S; Bailey, Y; Burisch, J; Elkjaer, M; Langholz, E; Laugesen, B; Lynge, E; Munkholm, P; O'Morain, C; Scherfig, H; Shuhaibar, M, 2010) |
| "333 patients with mild/moderate ulcerative colitis and 5-aminosalicylate acid treatment were randomised to either a web-group receiving disease specific education and self-treatment via http://www." | ( Avnstrøm, S; Bailey, Y; Burisch, J; Elkjaer, M; Langholz, E; Laugesen, B; Lynge, E; Munkholm, P; O'Morain, C; Scherfig, H; Shuhaibar, M, 2010) |
| "As the pathogenesis of ulcerative colitis (UC) is unknown, a causative therapy is lacking." | ( Braun, A; Ehehalt, R; Fazeli, S; Hanemann, A; Karner, M; Stoffels, S; Stremmel, W, 2010) |
| "Early diagnosis and treatment of ulcerative colitis (UC) is clinically challenging." | ( Chen, Y; Jiang, B; Kang, B; Liu, S; Lu, C; Lu, Y; Wang, H; Yang, X; Zhang, J; Zhao, X; Zhi, F, 2011) |
| "Adjusting therapy of patients with ulcerative colitis (UC) regarding their cytomegalovirus (CMV)--status." | ( Baryshnikov, EN; Drozdov, VN; Lazebnik, LB; Parfenov, AI; Shuliat'ev, IS, 2010) |
| "Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment." | ( Avellini, C; Fabro, M; Fiorino, G; Sorrentino, D; Szabo, H; Tabuso, M; Terrosu, G, 2011) |
| "The goals of treatment for ulcerative colitis (UC) are to induce and maintain corticosteroid-free remission, thereby reducing hospitalizations and surgeries and preventing longer-term disease complications including colorectal cancer." | ( La Nauze, RJ; Sparrow, MP, 2011) |
| "The study included 44 patients with ulcerative colitis (UC), which was implemented MSC transplantation, 40 patients with UC who received standard therapy with mesalazane (salofalka) 4-6 g/day and corticosteroids (prednisone)--1-2 mg/kg, azathioprine--1." | ( Gudkova, RB; Khomeriki, SG; Kniazev, OV; Konopliannikov, AG; Konopliannikova, OA; Lazebnik, LB; Mikhaĭlova, ZF; Parfenov, AI; Rogozina, VA; Ruchkina, IN; Shcherbakov, PL; Tsaregorodtseva, TM, 2010) |
| "In patients with steroid-refractory ulcerative colitis, cytomegalovirus infections were treated with intravenous ganciclovir." | ( Cheon, JH; Choi, CH; Han, DS; Jang, BI; Jung, SA; Kim, JS; Kim, WH; Kim, YH; Kim, YS; Park, YS; Yang, SK; Ye, BD, 2012) |
| "The treatment of ulcerative colitis (UC) can place a substantial financial burden on healthcare systems." | ( Mittendorf, T; Prenzler, A; von der Schulenburg, JM; Yen, L, 2011) |
| "Up to 40% of patients with ulcerative colitis (UC) fail to comply with 5-aminosalicylic acid (5-ASA) therapy." | ( Baker, R; Bankart, J; Mayberry, JF; Moshkovska, T; Smith, RM; Stone, MA, 2011) |
| "Patients with ulcerative colitis (UC) frequently require long-term therapy to prevent relapse." | ( Dewilde, S; Hodgkins, P; Lloyd, A; Solomon, D; Swinburn, P; Yen, L, 2012) |
| "Medical treatment of steroid-refractory ulcerative colitis (UC) is limited to either cyclosporine or infliximab." | ( Dean, KE; Hikaka, J; Huakau, JT; Walmsley, RS, 2012) |
| "Rat model of ulcerative colitis was established by intra-colonic administration of trinitrobenzenesulfonic acid (TNBS)." | ( Dong, L; Huang, Y, 2011) |
| "This report presents a patient with ulcerative colitis who developed Kaposi's sarcoma following treatment with long-term medium-dose azathioprine and additional corticosteroids." | ( Beneklı, M; Büyükberber, S; Cetın, B; Coşkun, U; Yildiz, R; Yilmaz, IB, 2011) |
| "Patients with chronic active ulcerative colitis (UC) are regarded as treatment failures and represent an area of high unmet medical need, as normally the only remaining option is colectomy." | ( Admyre, C; Löfberg, R; Lutfi, T; Malek, M; Musch, E; von Stein, OD; von Stein, P; Zargari, A, 2013) |
| "We report a case of a patient with ulcerative colitis and central serous retinopathy, which is a chronic ophthalmological condition that is frequently aggravated by corticosteroid treatment and may sometimes result in severe visual impairment." | ( Ben-Horin, S; Geyshis, B; Katz, G; Kopylov, U, 2013) |
| "A total of 153 patients with ulcerative colitis (UC) and 53 patients with Crohn's disease (CD), which at the time of the study received basic anti-inflammatory therapy for at least 1 year." | ( Drozdov, VN; Kniazev, OV; Lishchinskaia, AA; Noskova, KK; Parfenov, AI; Varvanina, GG, 2011) |
| "When treating patients with severe ulcerative colitis (UC), accurate prediction of drug efficacy contributes to early clinical decision-making." | ( Arai, M; Katsuno, T; Matsubara, H; Matsumura, T; Miyauchi, H; Nakagawa, T; Saito, K; Saito, M; Sato, T; Sazuka, S; Yokosuka, O, 2012) |
| "In the case of steroid resistance in ulcerative colitis, aminosalicylates, the above-mentioned immunomodulators, infliximab, adalimumab or calcineurin inhibitors such as ciclosporin or tacrolimus may be administered." | ( Frei, P; Lakatos, PL; Manz, M; Rogler, G; Safroneeva, E; Schoepfer, AM; Vavricka, SR; Wanner, R, 2012) |
| "Patients with extensive ulcerative colitis or with frequent relapses may benefit from a higher dose of maintenance therapy." | ( Feagan, BG; Macdonald, JK, 2012) |
| "Steroid-refractory ulcerative colitis (UC) remains a challenging condition warranting surgery upon failure of pharmacological treatment." | ( Barthel, D; Büning, J; Emmrich, J; Fellermann, K; Herrlinger, KR; Koc, H; Lehnert, H; Schmidt, KJ; Stange, EF, 2013) |
| "Of 415 patients with ulcerative colitis, 49 had been treated with sulfasalazine at some time." | ( Busto Bea, V; Garrido, E; López San Román, A; Martínez González, J; Mesonero Gismero, F; Parejo Carbonell, S, 2013) |
| "Patients with ulcerative colitis (UC) are treated with prednisolone (PSL), which causes adverse side effects." | ( Hiraishi, H; Hoshino, M; Kanke, K; Nakano, M; Tominaga, K, 2013) |
| "We established a mouse model of ulcerative colitis-associated colorectal cancer by treating the animals with azoxymethane (AOM) and dextran sulphate sodium (DSS), and investigated the inflammation-dysplasia-carcinoma sequence." | ( Chen, X; Gan, HT; Huang, XL; Li, Z; Liu, GX; Liu, YL, 2013) |
| "Studies have demonstrated that ulcerative colitis patients treated with 5-ASA have an overall decrease in the risk of developing colorectal carcinoma." | ( Dou, X; Graham, PM; Jia, Z; Li, JZ; Li, Y; Misra, HP; Zhu, H, 2013) |
| "The treatment of ulcerative colitis is based on systemic corticosteroids, immunomodulators such as cyclosporine and azathioprine and TNF-α antagonists." | ( Hartmann, F; Stein, J; Tannich, E, 2013) |
| "In patients with steroid-dependent ulcerative colitis, 6-month therapy with low dose of dexamethasone 21-phosphate allowed the withdrawal of oral steroids and the reversal of steroid-related adverse events in most patients while maintaining clinical remission (ClinicalTrials." | ( Andriulli, A; Annese, V; Bossa, F; Damonte, G; De Santo, E; Latiano, A; Magnani, M; Martino, G; Palmieri, O; Rossi, L; Serafini, S; Valvano, MR, 2013) |
| "Patients with mild to moderate ulcerative colitis (UC) were randomized to daily doses of oral Polyphenon E (400 mg or 800 mg of total EGCG daily, administered in split doses) or placebo in a double-blinded, placebo-controlled pilot study." | ( Beatty, K; Dryden, GW; Lam, A; McClain, CJ; Qazzaz, HH, 2013) |
| "Treatment for ulcerative colitis includes mostly systemic acting steroids for induction of remission and topically and systemically acting 5-ASA products and TNF antibodies for maintenance of remission." | ( Beglinger, C; Patuto, N, 2013) |
| "Patients with ulcerative colitis often require steroid therapy before definitive surgery and often receive perioperative steroids in a variety of doses." | ( Aytac, E; Costedio, MM; Erem, HH; Londono, JM; Vogel, JD, 2013) |
| "Clinical symptoms for ulcerative colitis were studied using Disease Activity Index (DAI) while myeloperoxidase assay marked the neutrophil infiltration in DSS and DMH treated groups." | ( Nehru, B; Sanyal, SN; Setia, S, 2014) |
| "Acetic acid ulcerative colitis (UC) is an experimental condition created due to intra-rectal administration of acetic acid which causes inflammation and ulceration in the lining of colon and rectum." | ( Bansal, D; Dubey, N; Ganeshpurkar, A; Pandey, V; Vishwakarma, N, 2015) |
| "Monitoring active ulcerative colitis (UC) is essential for making correct and timely treatment decisions." | ( Kiszka-Kanowitz, M; Nielsen, AM; Nordgaard-Lassen, I; Theede, K, 2014) |
| "Experimentally ulcerative colitis (UC) was induced by AA in animals pretreated with three different doses of GS leaves extract (50, 100, 200 mg/kg/day) and a single dose of mesalazine (MES, 300 mg/kg/day) for seven days." | ( Abuohashish, HM; Ahmed, MM; Al-Rejaie, SS; Aleisa, AM; Ola, MS; Parmar, MY, 2014) |
| "The primary therapeutic goals in ulcerative colitis (UC) are to maintain excellent quality of life (QOL) by treating flare-ups when they occur, and preventing flare-ups." | ( Hoffman, A; Jedel, S; Keshavarzian, A; Li, H; Merriman, P; Rajan, KB; Shaikh, M; Swanson, B; Voigt, R, 2014) |
| "Treatments for Crohn's disease (CD) and ulcerative colitis (UC) are not uniformly effective, thus necessitating dose changes, switching, and augmentation and carry adverse event risk, often requiring discontinuation, which reduces treatment benefits." | ( Davis, KL; Mody, R; Rubin, DT; Wang, CC, 2014) |
| "In light of symptom exacerbation of ulcerative colitis, increased inflammatory injury of colon mucosa shown by colonoscopy and elevated peripheral eosinophil count after mesalamine suppositories administration, and the Naranjo algorithm score of 10, the possibility of hypersensitivity reaction to mesalamine suppositories should be considered, warning us to be aware of this potential reaction after administration of mesalamine formulations even if it is the suppositories." | ( Ding, H; Hu, J; Hu, XY; Liu, XC; Mei, Q; Xu, JM, 2014) |
| "Among patients with steroid-refractory ulcerative colitis (UC) in whom a first rescue therapy has failed, a second line salvage treatment can be considered to avoid colectomy." | ( Beglinger, C; Bojic, D; Frei, P; Jojic, N; Juillerat, P; Mottet, C; Mwinyi, J; Protic, M; Radojicic, Z; Rogler, G; Schoepfer, A; Seibold, F; Vavricka, S, 2014) |
| "We present three patients with ulcerative colitis, all treated with mesalazine, in whom unexplained lung disease developed." | ( Bestry, I; Kacprzak, A; Kuś, J; Langfort, R; Siemion-Szcześniak, I; Szturmowicz, M, 2014) |
| "Tacrolimus in refractory ulcerative colitis often serves as a bridge to long-term maintenance therapy with thiopurines." | ( Boschetti, G; Bouhnik, Y; Chauvenet, M; Flourié, B; Moussata, D; Nancey, S; Roblin, X; Stefanescu, C; Stroeymeyt, K, 2014) |
| "Patients with ulcerative colitis still need effective therapy without major side effects." | ( Akyol, M; Ataseven, H; Topal, F; Tuzcu, M; Tuzcu, N; Yonem, O, 2014) |
| "Japanese ulcerative colitis (UC) patients receiving acute induction therapy with 4." | ( Akazawa, Y; Ichikawa, T; Isomoto, H; Makiyama, K; Matsumura, M; Nakao, K; Nishiyama, H; Ohba, K; Ohnita, K; Takeshima, F; Yamaguchi, N; Yamakawa, M; Yamao, T, 2014) |
| "In cases of ulcerative colitis with megacolon, treatment with oral tacrolimus is recommended, thereby avoiding steroid dependency and improving the long-term prognosis." | ( Abe, Y; Fujiwara, K; Fukunishi, S; Higuchi, K; Iguchi, M; Inoue, T; Ishida, K; Kakimoto, K; Masuda, D; Narabayashi, K; Nouda, S; Okada, T; Sakanaka, T; Takeuchi, T; Umegaki, E; Yorifuji, N, 2014) |
| "We included 196 IBD patients [45 with ulcerative colitis (UC), 68 with Crohn's disease (CD), and 83 with intestinal Behçet's disease (BD)] who were treated with AZA/6-MP and achieved remission between January 2006 and December 2012." | ( Cheon, JH; Hong, SP; Kim, DH; Kim, TI; Kim, WH; Park, MS; Park, SJ, 2015) |
| "The classical aim of the treatment of ulcerative colitis is to induce and maintain remission." | ( García-Sánchez, V; Iglesias-Flores, E, 2011) |
| "A relapse of ulcerative colitis was treated with corticosteroids (CS) and IFX as rescue therapy." | ( Cecere, S; Hansen, LK; Thøgersen, T, 2014) |
| "Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy." | ( Jeen, YT; Park, SC, 2015) |
| "Forty-four ulcerative colitis patients who were treated with tacrolimus in three institutes during 2009-2013 were retrospectively reviewed." | ( Hanai, H; Iida, T; Ikeya, K; Kawasaki, S; Maruyama, Y; Sugimoto, K; Watanabe, F, 2015) |
| "Physicians traditionally treat ulcerative colitis (UC) using a step-up approach." | ( Fournier, N; Rogler, G; Safroneeva, E; Schoepfer, AM; Straumann, A; Vavricka, SR, 2015) |
| "Treatment of mesalazine, an anti-ulcerative colitis drug, down-regulated Foxp3 and IL-17 expression in BTLA positive T cells along with attenuated severity for colitis." | ( Fu, XX; Kong, B; Wang, CY; Wang, WD; Xiang, WY; Xu, JF; Zeng, JC; Zhang, HX; Zhang, JA; Zheng, XB; Zhong, J; Zhu, B, 2015) |
| "Identifying ulcerative colitis (UC) patients with increased risk of colectomy is essential for appropriate treatment." | ( Cvancarova, M; Høivik, ML; Moum, B; Solberg, IC, 2015) |
| "We report a 22 year-old male with ulcerative colitis in treatment with mesalazine and prednisone presenting with headache and speech disturbances." | ( Bagattini, JC; Calcagno, GP; Chiarella, M; Cohen, H; Forster, TA, 2015) |
| "Induction of ulcerative colitis in rats was performed by intra-rectal acetic acid (5% v/v) administration for 3 consecutive days." | ( Abdel-Galil, AG; El-Gowelli, HM; Ibrahim, ER; Saad, EI, 2015) |
| "A 52-year-old woman with ulcerative colitis was admitted to our hospital for an ulcerative colitis flare-up under salazosulfapyridine therapy." | ( Chayama, K; Hayashi, R; Nagai, K; Sagami, S; Tanaka, S; Ueno, Y, 2015) |
| "She had poorly controlled ulcerative colitis and was treated with high doses of prednisolone, infliximab, acetaminophen and lansoprazole." | ( Aruga, T; Fukuda, K; Kamiyama, T; Kobayashi, K; Miyake, Y; Sasaki, S; Sueki, H; Watanabe, H, 2016) |
| "She was under treatment for ulcerative colitis." | ( Kanno, S; Mochizuki, H; Ogawa, R; Oikawa, T; Shibuya, S; Shijo, T, 2015) |
| "Patients with ulcerative colitis (UC) who achieve remission with corticosteroids often relapse after tapering or discontinuation; alternative treatments limiting steroid exposure and UC relapse would be beneficial." | ( Barrett, AC; Bortey, E; Forbes, WP; Gordon, GL; Lichtenstein, GR; Murthy, U; Paterson, C; Pruitt, R; Sedghi, S; Zakko, S, 2016) |
| "Approximately 25% of patients with ulcerative colitis [UC] experience a severe flare requiring steroid therapy to avoid colectomy." | ( Ido, A; Komaki, F; Komaki, Y; Sakuraba, A, 2016) |
| "The management of patients with ulcerative colitis who are dependent on corticosteroid for control of symptoms, or refractory to corticosteroids or standard immunosuppressive therapy, is challenging." | ( Day, AS; Eliadou, E; Gearry, RB; Inns, SJ; Rowbotham, DS; Schultz, M; Thompson-Fawcett, MW; Walmsley, R, 2015) |
| "They were all diagnosed as ulcerative colitis and treated with mesalazine orally." | ( Abe, T; Akiyama, N; Matsui, T; Nozue, T; Suda, T; Yokomura, K, 2015) |
| "In the present study, experimental ulcerative colitis was induced in male BALB/c mice by the administration of 5% dextran sulfate sodium (DSS) for 7 days, followed by treatment with UA for another 7 days." | ( Chai, F; Gao, L; Guo, L; Liu, B; Liu, S; Piao, X, 2016) |
| "Patients with extensive ulcerative colitis or with frequent relapses may benefit from a higher dose of maintenance therapy." | ( Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016) |
| "Pediatric Ulcerative Colitis Activity Index is a valid predictive tool that can guide clinicians in evaluating response to therapy." | ( Kugathasan, S; Romano, C; Syed, S; Valenti, S, 2016) |
| "Children with ulcerative colitis treated with AZA within 24 months of diagnosis were included." | ( Aloi, M; Alvisi, P; Arrigo, S; Bramuzzo, M; Civitelli, F; Distante, M; DʼArcangelo, G; Gasparetto, M; Gatti, S; Illiceto, MT; Martelossi, S; Martinelli, M; Pellegrino, S; Valenti, S, 2016) |
| "The medical treatment of ulcerative colitis (UC) has seen a change towards a more active attitude during recent years, including both the use of more traditional drugs as well as new biological substances." | ( Holmström, T; Karlbom, U; Rönnblom, A; Sjöberg, D; Tanghöj, H; Thörn, M, 2016) |
| "We produced a mouse model of ulcerative colitis by administering DSS for 5 days and irradiated the eye with UVB or UVA for each day of the DSS treatment period." | ( Hiramoto, K; Sato, EF; Yamate, Y, 2016) |
| "Treatment of active ulcerative colitis is associated with incomplete efficacy, adverse events, and loss of response." | ( Adar, T; Chowers, Y; Dotan, I; Fich, A; Goldin, E; Israeli, E; Levy-Nissenbaum, E; Shteingart, S; Soreq, H, 2016) |
| "Crohn's disease (CD) and ulcerative colitis (UC) have different immunological mechanisms, while both of them are potential targets of vitamin D treatment." | ( Du, J; Ge, X; Liu, L; Liu, T; Shi, Y; Teng, X; Wang, E; Zhao, Q, 2016) |
| "Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4." | ( Buscemi, S; Carini, F; Damiani, P; Damiano, G; Gerges-Geagea, A; Jurjus, A; Lo Monte, AI; Marino Gammazza, A; Palumbo, VD; Romeo, M; Tomasello, G, 2016) |
| "Patients with active ulcerative colitis can benefit from YNBY as an adjuvant treatment, which shortens the time of disease remission, relieves the symptoms and improves the quality of life of the patients." | ( Diao, N; Gu, YX; Li, MS; Zhao, WZ; Zhu, XT, 2016) |
| "Of the 79 patients with ulcerative colitis treated with infliximab, seven (8." | ( Desai, D; Puri, AS; Sachdeva, S; Sood, A, 2017) |
| "Of the 1279 adult patients with ulcerative colitis, 25 patients were treated with AZA for refractory UP (median disease duration 4." | ( Bouguen, G; Bretagne, JF; Conroy, G; Delobel, JB; Mallet, AL; Peyrin-Biroulet, L; Roblin, X; Siproudhis, L, 2017) |
| "Sixty-one Japanese patients with ulcerative colitis treated with tacrolimus were enrolled retrospectively." | ( Endo, K; Hiramoto, K; Kakuta, Y; Kanazawa, Y; Kimura, T; Kinouchi, Y; Kuroha, M; Negoro, K; Onodera, M; Shiga, H; Shimosegawa, T, 2017) |
| "Efficacy of maintenance therapy in ulcerative colitis (UC) in the remission stage has been reported to depend on release profile or dosing regimen of oral 5-aminosalicylic acid (5-ASA) products used." | ( Hanai, H; Hibi, T; Kochi, S; Nagahori, M; Nakamura, S; Omuro, S; Watanabe, M; Yamamoto, T, 2017) |
| "We present a case of a patient with ulcerative colitis and recurrent CD infection successfully treated with FT." | ( Izquierdo Romero, M; Mancebo Mata, A; Varela Trastoy, P, 2017) |
| "Guided by the Pediatric Ulcerative Colitis Activity Index (PUCAI), patients received initial standardised treatment with mesalazine (PUCAI 10-30) oral corticosteroids (PUCAI 35-60), or intravenous corticosteroids (PUCAI ≥65)." | ( Baker, SS; Baldassano, RN; Benkov, K; Boyle, B; Britt, A; Collins, MH; Davis, S; Denson, LA; Dubinsky, M; Evans, J; Gotman, N; Griffiths, AM; Guthery, SL; Heyman, M; Hyams, JS; Kappelman, MD; Keljo, DJ; Kugathasan, S; LeLeiko, NS; Mack, DR; Markowitz, J; Marquis, A; Moulton, D; Noe, J; Oliva-Hemker, M; Otley, A; Patel, A; Pfefferkorn, M; Rosh, J; Rufo, P; Sauer, CG; Saul, B; Serrano, J; Spada, KL; Strople, J; Sudel, B; Sylvester, FA; Tangpricha, V; Venkateswaran, S; Wali, P; Walters, T; Wang, J; Ziring, D, 2017) |
| "Administration of ethanol to mice with ulcerative colitis intensified the disease-activity index with marked reduction in colon length, colon mass index, body weight gain, and organo-somatic indices of testes and epididymis when compared with the DSS-alone group." | ( Adedara, IA; Ajayi, BO; Awogbindin, IO; Farombi, EO, 2017) |
| "Adherence is pivotal but challenging in ulcerative colitis (UC) treatment." | ( Burger, DM; Drenth, JPH; Hoentjen, F; Peters, W; Römkens, TEH; Te Morsche, R, 2018) |
| "treatment guidelines for ulcerative colitis (UC) not yet established." | ( Halimkesuma, CC; Simadibrata, M; Suwita, BM, 2017) |
| "Mesalamine is commonly used to treat ulcerative colitis (UC)." | ( Daly, MJ; Huang, H; Kaplan, JL; Moran, CJ; Rivas, M; Winter, HS, 2018) |
| "Treatment options for ulcerative colitis (UC) remain limited because conventional therapies do not succeed at controlling the disease in a considerable percentage of patients, while up to 30% of those receiving biologics are primary nonresponders and 10%-20% lose response per year, requiring an increase in the treatment dose or the use of a different drug." | ( Bonovas, S; D'Amico, F; Danese, S; Peyrin-Biroulet, L, 2018) |
| "We induced a mouse model of ulcerative colitis by administering DSS for 5 days, and administered UVB eye irradiation on each day of the DSS treatment period." | ( Hiramoto, K; Kasahara, E; Sato, EF; Yamate, Y, 2018) |
| "In the treatment of steroid-resistant ulcerative colitis with infliximab and cyclosporine, there is no difference between the two treatments on short-term and long-term results." | ( Wu, D; Yang, Z; Yao, L; Zhao, C, 2018) |
| "A 56-year-old man with ulcerative colitis was treated with mercaptopurine." | ( Gerding, MN; van der Burg, M, 2018) |
| "The patient was diagnosed with ulcerative colitis and received remission induction therapy with prednisolone." | ( Arisaka, O; Arisaka, T; Hiraishi, H; Irisawa, A; Kanazawa, M; Sugaya, T; Takahashi, F; Takenaka, K; Tominaga, K, 2019) |
| "Men with ulcerative colitis were more likely to undergo treatment consistent with long-term remission or cure, including maintenance medications and definitive surgery." | ( Bundorf, MK; Kin, C; Morris, AM; Park, KT; Sceats, LA, 2019) |
| "Murine ulcerative colitis (UC) was induced by treatment with 2." | ( He, JF; Jin, DX; Luo, XG; Zhang, KQ; Zhang, TC, 2019) |
| "Treatment pathways for ulcerative colitis (UC) and Crohn's disease (CD) are shifting to a more individualized, risk-stratified approach." | ( Cao, C; Dulai, PS; Lasch, K; Osterman, MT; Riaz, F; Sandborn, WJ, 2019) |
| "Observational, cohort study of ulcerative colitis (UC) patients in clinical remission at least 6 months on 5-ASA monotherapy maintenance prescribed by an electronic management program." | ( Anton, R; Ballester, MP; Bosca-Watts, MM; Fullana, M; Marti-Aguado, D; Minguez, M; Mora, F; Navarro-Cortes, P; Romero, E; Sanchez, A; Tosca, J, 2019) |
| "The link between ulcerative colitis and CMV infection and the efficacy of antiviral therapy in these individuals have been demonstrated." | ( Binicier, OB; Sari, SO, 2019) |
| "Acute severe ulcerative colitis unresponsive to systemic steroid treatment is a life-threatening medical condition requiring hospitalization and often colectomy." | ( Belling, N; Gauss, A; Hoffmann, P; Krisam, J; Pfeiffenberger, J; Wehling, C, 2019) |
| "We prepared a mouse ulcerative colitis model by administering DSS for 7 d along with high-dose vitamin C each day during DSS treatment." | ( Goto, K; Hiramoto, K; Kondo, K; Ooi, K; Sekijima, H; Yamate, Y, 2019) |
| "The treatment of ulcerative colitis (UC) is based on conventional therapies (aminosalicylates, corticosteroids, and immunosuppressants) and when these are ineffective, biologic drugs." | ( Antonelli, E; Bassotti, G; Torti, G, 2019) |
| "Treatment targets for ulcerative colitis are evolving towards achievement of endoscopic improvement and remission in addition to symptom resolution." | ( D'Haens, G; Dulai, PS; Feagan, BG; Jairath, V; Ma, C; Narula, N; Peyrin-Biroulet, L; Sandborn, WJ; Singh, S; Vande Casteele, N; Vermeire, S, 2020) |
| "Although most patients with ulcerative colitis should be given topical treatment, different studies have shown that they are underused in clinical practice." | ( Barreiro-de Acosta, M; Domènech, E; Esteve, M; Ginard, D; Gisbert, JP; Marín-Jiménez, I; Mínguez, M; Ricart, E, 2020) |
| "The IL10-producing B cells of both ulcerative colitis and Crohn disease patients were reduced at the initiation of IFX therapy, whereas TNFα-producing transitional CD24hiCD38hi B cells in ulcerative colitis patients were increased compared with those in healthy control patients." | ( Allabauer, I; Christoph, J; Ehrsam, C; Hess, M; Hoerning, A; Kaspar, S; Metzler, M; Rascher, W; Rechenauer, T; Rieger, D; Rückel, A; Schmidt, H; Schnell, A; Schwarz, B; Siebenlist, G; Wahlbuhl, M; Weber, S; Werner, F; Woelfle, J, 2021) |
| "Therefore, in diagnosing and treating ulcerative colitis, noninvasive, low-cost methods for predicting mucosal healing using useful biomarkers are required in the clinical setting." | ( Chayama, K; Hayashi, R; Ito, M; Kumada, J; Naito, T; Nomura, M; Oka, S; Takigawa, H; Tanaka, S; Ueno, Y; Wakai, M, 2020) |
| "Treatment for ulcerative colitis often requires the administration of immunosuppressive therapy." | ( Bell, A; Fayyaz, F; Healey, S; Said, W, 2020) |
| "C57Bl/6 mice were used to establish the ulcerative colitis model by exposure to dextran sulfate sodium (DSS), and divided into three experimental groups: eptifibatide-treated (150 µg/day intraperitoneally; n = 10), ticagrelol-treated (1 mg/day via gastric tube; n = 10), and DSS-control (plain drinking water; n = 10)." | ( Brcerevic, IA; Cikota, BM; Doder, RB; Magic, ZM; Majstorovic, IJ; Manojlovic, NS; Obradovic, SD; Perisic, NJ; Petrovic, MD; Petrovic, SS; Rancic, NK; Tarabar, DK; Vasiljevska, MM, 2020) |
| "The effectiveness of plants in treating ulcerative colitis has been determined." | ( Akkol, EK; Karpuz, B; Khan, H; Sobarzo-Sánchez, E, 2020) |
| "This analysis in patients with ulcerative colitis who require treatment with biologics or tofacitinib demonstrates that continuing 5-ASA therapy is not a cost-effective strategy." | ( Huang, E; Patel, S; Rubin, DT; Shaffer, SR, 2021) |
| "In patients with mesalazine-refractory ulcerative colitis, systemic corticosteroids are the treatment of choice." | ( Derova, J; Fellermann, K; Greinwald, R; Jonaitis, L; Nacak, T; Rácz, I; Schiefke, I; Wehrum, S, 2020) |
| "Patients with mesalazine-refractory ulcerative colitis discontinued mesalazine at baseline and received 9 mg prolonged release budesonide granules daily for 8 weeks in this open-label, phase IIa study, followed by a 2-week follow-up phase wherein patients continued treatment on alternate days (EudraCT number 2014-005635-14; ClinicalTrials." | ( Derova, J; Fellermann, K; Greinwald, R; Jonaitis, L; Nacak, T; Rácz, I; Schiefke, I; Wehrum, S, 2020) |
| "We treated a mouse model of ulcerative colitis induced by DSS (dextran sulfate sodium) with PE." | ( Guo, W; Li, G; Liu, K; Zhang, J, 2020) |
| "Patients with acute severe ulcerative colitis avoiding early colectomy are at risk of long-term colectomy, especially if previously exposed to antitumour necrosis factor-α agents or if rescue therapy during the acute attack was required because of steroid refractoriness." | ( Allocca, M; Aratari, A; Armuzzi, A; Barberio, B; Bezzio, C; Bodini, G; Cosintino, R; Costa, F; Festa, S; Mazzuoli, S; Mocci, G; Papi, C; Principi, M; Pugliese, D; Ribaldone, DG; Scribano, ML; Spagnuolo, R; Vernia, P; Zerboni, G, 2021) |
| "He was suspected of having ulcerative colitis, and administration of 2400mg/day of oral mesalazine was initiated." | ( Ikeuchi, H; Kodama, R; Koh, Y; Nagaya, T; Saegusa, H; Ushimaru, H, 2020) |
| "About one-third of patients with severe ulcerative colitis (UC) do not respond to corticosteroid therapy and receive rescue therapy with infliximab or cyclosporine." | ( Chiba, M; Ishii, H; Komatsu, M; Nakane, K; Obara, Y; Ohno, H; Tozawa, H; Tsuda, S; Tsuji, T, 2020) |
| "A pregnant woman with severe ulcerative colitis was treated with a dose of mesalazine 4,000 mg/day from early gestation to delivery." | ( Kuboi, T; Nii, K; Okada, H; Okazaki, K, 2021) |
| "Of the 13,499 patients with ulcerative colitis treated, 17 adult patients with ulcerative colitis and anal dysplasia and/or anal squamous cell carcinoma were included in the study: 6 had a diagnosis of anal squamous cell carcinoma, 8 had high-grade squamous intraepithelial lesions, and 3 had low-grade squamous intraepithelial lesions." | ( Click, B; Hull, TL; Lightner, AL; McMichael, J; Regueiro, M; Steele, SR; Vaidya, P, 2021) |
| "A total of 130 ulcerative colitis patients admitted to our hospital from August 2018 to March 2020 were included and divided into the experimental group (65 patients with mesalazine plus somatostatin and bifid triple viable capsules for treatment) and the control group (65 patients treated with mesalazine plus somatostatin) using the random number table method." | ( Li, S; Xiao, D; Yin, Y; Zou, Y, 2021) |
| "The effective treatment of ulcerative colitis (UC) poses substantial challenges, and the aetiopathogenesis of UC is closely related to infectious, immunological and environmental factors." | ( Du, Y; Gu, Y; Jiang, L; Liu, J; Tang, X; Yang, M, 2021) |
| "Treatment for moderate-to-severe ulcerative colitis (UC) includes medical therapies such as immunosuppressive agents or surgical options such as colectomy." | ( Bewtra, M; Chu, BK; Scott, FI, 2021) |
| "An 11-year-old boy diagnosed with ulcerative colitis (UC) was in clinical remission, with treatment involving 5-aminosalicylic acid." | ( Fujita, Y; Sugaya, T; Tanaka, T; Tominaga, K; Yoshihara, S, 2021) |
| "Clinical response was defined for ulcerative colitis (UC) as a reduction of partial Mayo score ≥3 with reduction in rectal bleeding score of at least 1 and a final rectal bleeding subscore of 0-1 at Week 12 of therapy." | ( Doecke, JD; Eqbal, A; Martin, A; Patrick, D, 2023) |
| "A 51-year-old Caucasian woman with ulcerative colitis was treated with mesalazine." | ( Garrido, I; Lopes, J; Lopes, S; Macedo, G; Santos, AL, 2021) |
| "Adjuvant curcumin therapy for ulcerative colitis has become increasingly popular, but its efficacy and safety of which is still controversial." | ( Li, X; Miao, M; Wang, N; Wei, L; Yin, J, 2022) |
| "The treatment spectrum for ulcerative colitis has greatly increased in recent years." | ( Kucharzik, T, 2022) |
| "Treatment options for acute severe ulcerative colitis (ASUC) are limited." | ( Afif, W; Benoit, N; Bessissow, T; Jairath, V; Lakatos, PL; McCurdy, JD; Narula, N; Rosenfeld, G; Sedano, R; Xiao, Y, 2022) |
| "A 32-year-old woman with ulcerative colitis currently treated with azathioprine and adalimumab was referred to our rheumatology clinic due to pain and swelling in her knees and finger joints." | ( Jensen, MD; Lomborg, N, 2022) |
| "In acute severe ulcerative colitis (ASUC), first-line therapy is intravenous (IV) steroids." | ( Juillerat, P; Laharie, D; Nachury, M; Pellet, G; Roblin, X; Veyrard, P, 2023) |
| "Recent progress in ulcerative colitis (UC) treatment has been remarkable, and various medications have been applied." | ( Asaeda, K; Dohi, O; Hotta, Y; Inoue, K; Ishikawa, T; Itoh, Y; Kajiwara, M; Kamada, K; Kashiwagi, S; Katada, K; Kishimoto, M; Konishi, H; Minagawa, Y; Mizushima, K; Naito, Y; Okayama, T; Takagi, T; Tanaka, M; Uchiyama, K; Yasuda, H; Yoshida, N, 2022) |
| "The outcomes of ulcerative colitis (UC) treatment remain unsatisfactory." | ( Deng, L; Huang, J; Li, M; Lin, Y; Liu, X; Lu, Z; Tan, W; Wang, S; Zhang, R, 2022) |
| "Acute severe ulcerative colitis (basal Lichtiger score > 10) patients who did not respond to 40 mg intravenous methylpredniso- lone therapy after 3-5 days were included in the study." | ( Akyüz, F; Baran, B; Beşışık, F; Çavuş, B; Demir, K; Evirgen, S; Göktürk, S; İliaz, R; Karaca, Ç; Kaymakoğlu, S; Mutluay Soyer, Ö; Örmeci, A; Pınarbaşı, B, 2022) |
| "difficile infection among patients with ulcerative colitis receiving tofacitinib were infrequent; cases were mild–moderate in severity, and most resolved with treatment." | ( Armuzzi, A; Baumgart, DC; Connelly, SB; Gecse, K; Kinnucan, JA; Kwok, KK; Loftus, EV; Salese, L; Su, C; Woolcott, JC, 2023) |
| "Treating moderate to severe ulcerative colitis (UC) has been enriched by the increasing number of drugs available for this disease." | ( Antonelli, EK; Bassotti, G; Del Sordo, R; Morelli, O; Villanacci, V, 2022) |
| "Tacrolimus therapy for ulcerative colitis is ineffective in certain patients; these patients require biologics or colectomy." | ( Asai, Y; Furuta, T; Hamaya, Y; Ishida, N; Iwaizumi, M; Miyazu, T; Osawa, S; Sugimoto, K; Tamura, S; Tani, S; Yamade, M, 2022) |
| "XLP might treat ulcerative colitis by regulating the TLR4/MyD88/NF-κB signaling pathway." | ( Dai, Y; Ding, K; Hu, Y; Jiang, J; Li, P; Lu, Q; Zhao, M; Zhao, T; Zhu, J, 2023) |
| "Curcumin's role in the treatment of ulcerative colitis (UC) has been proven by numerous studies, but its preventive administration, with the aim of reducing the remission episodes that are characteristic of this disease, must be further investigated." | ( Hales, D; Kiss, B; Muntean, DM; Neag, MA; Porfire, A; Rațiu, IA; Sesărman, A; Ștefan, MG; Tefas, LR; Tomuță, I, 2022) |
| "Anti-inflammatory drugs for ulcerative colitis (UC) treatment should specifically penetrate and accumulate in the colon tissue." | ( Fu, H; Hu, J; Hu, Y; Kang, L; Li, X; Wen, Z; Yang, X; Ye, X; Zhang, S, 2022) |
| "Patients with ulcerative colitis (UC) regard rapid onset of action among the most important aspects of their treatment." | ( Danese, S; Dinoso, J; Feagan, BG; Ferrante, M; Hibi, T; Hsieh, J; Le Brun, FO; Loftus, EV; Oortwijn, A; Peyrin-Biroulet, L; Ritter, T; Rogler, G; Sandborn, WJ; Schreiber, S; Vermeire, S; Yun, C, 2023) |
| "Adults with ulcerative colitis and health-care professionals treating inflammatory bowel disease." | ( Barr, A; Bedford, H; Blackwell, S; Coates, E; Dames, N; Hind, D; Lee, M; Lobo, A; Probert, C; Sebastian, S; Shackley, P; Totton, N; Wickramasekera, N, 2022) |
| "A woman in her 30s was diagnosed with ulcerative colitis (UC) 4 years ago and treated with tacrolimus, azathioprine, and prednisolone 5mg (PSL)." | ( Hashimoto, Y; Hosaka, H; Itoi, Y; Kasuga, K; Kita, A; Kuribayashi, S; Sato, K; Tanaka, H; Uraoka, T, 2022) |
| "5-ASA is used as first-line therapy for ulcerative colitis." | ( Kanai, T; Kiyohara, H; Mikami, Y; Mizushima, I; Suzuki, S; Tsunoda, J, 2023) |
| "The early outcomes of ulcerative colitis (UC) after rescue therapy with cyclosporine A (CyA) are well known." | ( Eronen, H; Helavirta, I; Huhtala, H; Ilus, T; Jussila, A; Oksanen, P, 2023) |
| "The early outcomes of ulcerative colitis (UC) after rescue therapy with cyclosporine A (CyA) are well known." | ( Eronen, H; Helavirta, I; Huhtala, H; Ilus, T; Jussila, A; Oksanen, P, 2023) |
| "The early outcomes of ulcerative colitis (UC) after rescue therapy with cyclosporine A (CyA) are well known." | ( Eronen, H; Helavirta, I; Huhtala, H; Ilus, T; Jussila, A; Oksanen, P, 2023) |
| "The long-term outcomes of Ulcerative colitis (UC) after discontinuation of biological therapy are largely unknown." | ( Beilfuss, J; Florholmen, J; Goll, R; Gundersen, M; Johnsen, KM; Kileng, H; Moe, ØK; Sørbye, SW, 2022) |
| "The long-term outcomes of Ulcerative colitis (UC) after discontinuation of biological therapy are largely unknown." | ( Beilfuss, J; Florholmen, J; Goll, R; Gundersen, M; Johnsen, KM; Kileng, H; Moe, ØK; Sørbye, SW, 2022) |
| "The long-term outcomes of Ulcerative colitis (UC) after discontinuation of biological therapy are largely unknown." | ( Beilfuss, J; Florholmen, J; Goll, R; Gundersen, M; Johnsen, KM; Kileng, H; Moe, ØK; Sørbye, SW, 2022) |
| "To establish ulcerative colitis mice model, at the beginning of the 4th week, mice maintained on the diet with or without triclosan were treated with 2% Dextran sulfate sodium(DSS) in drinking water for 1 week." | ( Haikun, W; Jingyi, L; Lanfang, Y; Liu, J; Ping, Y; Tao, Y, 2022) |
| "To establish ulcerative colitis mice model, at the beginning of the 4th week, mice maintained on the diet with or without triclosan were treated with 2% Dextran sulfate sodium(DSS) in drinking water for 1 week." | ( Haikun, W; Jingyi, L; Lanfang, Y; Liu, J; Ping, Y; Tao, Y, 2022) |
| "To establish ulcerative colitis mice model, at the beginning of the 4th week, mice maintained on the diet with or without triclosan were treated with 2% Dextran sulfate sodium(DSS) in drinking water for 1 week." | ( Haikun, W; Jingyi, L; Lanfang, Y; Liu, J; Ping, Y; Tao, Y, 2022) |
| "As potential candidates for treating ulcerative colitis (UC), polysaccharides have been attracting extensive interest in recent years." | ( Chen, C; Chen, S; Cui, SW; Dong, N; Fang, Q; Nie, S; Wang, J; Zhang, Y, 2023) |
| "For patients with moderate to severe ulcerative colitis, the first line for induction therapy options includes biologic agents (with or without an immunomodulator) or glucocorticoids." | ( Basnet, BK; Bhandari, A, 2022) |
| "As the first-line drug to treat ulcerative colitis (UC), long-term use of glucocorticoids (GCs) produces severe toxic and side effects." | ( Deng, SJ; Dong, K; Guan, ZL; Guo, ZY; He, BY; Leng, X; Ma, RR; Wang, DY; Xing, JF; You, CY, 2023) |
| "Patients with extensive ulcerative colitis demonstrate a higher risk for new-onset arthralgia, whereas, concomitant treatment with azathioprine appears to be protective." | ( Bamias, G; Benetou, V; Gaki, A; Giotis, I; Kitsou, V; Kokkotis, G; Lagiou, P; Leonidakis, G; Leontidis, N; Michopoulos, S; Orfanos, P; Stoupaki, M; Tzouvala, M; Zampeli, E, 2023) |
| "In a woman with ulcerative colitis associated arthritis, refractory to biologic therapy, both arthritis and colitis improved with tofacitinib." | ( Haq, SA; Momen Majumder, MS; Rasker, JJ, 2023) |
| "In vivo, dextran sulfate sodium-induced ulcerative colitis (UC) symptoms were significantly alleviated after oral administration, accompanied by reduced levels of inflammatory factors." | ( Chen, L; Fu, H; Hu, J; Hu, Y; Kang, L; Li, X; Wen, Z; Yang, X; Ye, X; Zhang, S; Zhu, S, 2023) |
| "Despite rescue therapy, acute severe ulcerative colitis (ASUC) is associated with a high risk of colectomy, while treatment options remain limited." | ( Christodoulou, DK; Fousekis, FS; Katsanos, KH; Mpakogiannis, K; Narula, N, 2023) |
| "A total of 108 IBD patients (ulcerative colitis [UC], 56; Crohn's disease [CD], 52) who received treatment at Sapporo Medical University Hospital between August 2020 and September 2021 were enrolled." | ( Hayashi, Y; Ichimiya, T; Ishigami, K; Itoi, T; Kazama, T; Nakase, H; Takahashi, S; Yokoyama, Y, 2023) |
| "A patient diagnosed with ulcerative colitis undergoing januskinase (JAK)-inhibitor therapy developed acuteappendicitis as an unusual complication or as a visceral side effect of immunosuppressive/anti-inflammatory therapy." | ( Croner, RS; Eger, KI; March, C; Meyer, F; Weber, F, 2023) |
| "Experimental ulcerative colitis was induced in rats by intrarectal acetic acid administration." | ( Bhatt, LK; Parihar, N, 2023) |
| "The clinical treatment of ulcerative colitis (UC) faces great challenges due to lifetime medication." | ( Huang, X; Liu, J; Wang, Y; Yan, X; Zhang, T, 2023) |
| "The mean decline in Pediatric Ulcerative Colitis Activity Index scores from admission to discharge in those treated with IFX (31." | ( Ajithkumar, A; Bogursky, A; Bousvaros, A; Lillehei, C; Liu, E; Manokaran, K; Rufo, PA; Spaan, J; Weil, BR; Weinbren, N; Zalieckas, JM; Zimmerman, LA, 2023) |
| "(AMP) in treating ulcerative colitis as the example, we checked the effects of AMP on tryptophan metabolites." | ( Feng, WW; Hu, P; Jiang, Z; Liu, J; Yan, X; Zeng, Y, 2023) |
| "Despite the progress in the therapy of ulcerative colitis (UC), long-lasting UC remission can hardly be achieved in the majority of UC patients." | ( Chen, T; Li, D; Li, J; Liang, W; Lin, X; Pan, L; Qin, X; Wang, Q, 2023) |
| "The majority of patients with ulcerative colitis starting tofacitinib in this real-world study continued therapy at 12 months; there was a reduction in the use of steroids, and a decrease in healthcare resournce utilization and costs." | ( Chiorean, M; Gruben, D; Ha, C; Hur, P; Khan, NH; Sharma, PP, 2023) |